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In allergic diseases such as allergic dermatitis, allergic asthma and allergic 
rhinitis, mast cells are the key effector cells for the early response upon the 
challenge of allergens. The IgE-mediated degranulation of mast cells is a 
well-known mechanism in initiating allergic inflammation. However, the detailed 
immunological aspect and response of mast cells are not well defined. The 
process of activation, interaction between leukocytes and the underlying 
intra-cellular signaling mechanisms of mast cells are far more complicated. 
In this study, we investigated the roles of mast cells in mediating allergic 
inflammation in two aspects. Firstly, we studied the effect of mast cell-specific 
protease chymase on human eosinophils. Secondly, we evaluated the expression 
of Toll-like receptor (TLR) to human mast cell line (HMC)-l cells. The 
responses of HMC-1 cells upon challenges by TLR ligands were also 
investigated. By using cytometric beads array and enzyme-linked 
immunosorbent assay, chemokines or inflammatory cytokines released by 
chymase-treated eosinophils were quantified. To determine the surface 
expression of adhesion molecules, flow cytometry was applied for 
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immunofluorescent staining. Besides, we also investigated the intracellular 
signaling pathway regulating the mentioned responses. 
In the first part, results showed mast cell protease chymase could induce the 
secretion of chemokines CXCLl, CXCL8 and CCL2, and inflammatory cytokine 
interleukin-6. Surface expression of adhesion molecules CD 18 was upregulated 
after chymase treatment. Moreover, chymase could increase viability and 
promote the migratory property of eosinophils. The above effects were regulated 
by p38 mitogen-activated protein kinase pathway, extracellular signal-regulated 
protein kinase (ERK) pathway, Janus kinase/signal transducers and activators of 
transcriptions pathway, phosphoinositide 3-kinase pathway and nuclear 
factor-KB pathway. 
In the second part, we found that HMC-1 cells could express TLRl, TLR2, 
TLR4, TLR5, TLR6，TLR7 and TLR9. By stimulating HMC-1 cells with TLR 
ligands, only TLR7 ligand Imiquimoid could increase the surface expression of 
intermolecular adhesion molecule (ICAM)-l and ICAM-3. The upregulations of 




In conclusion, the above findings could shed light on how mast cells actively 
participate in allergic inflammation. By understanding the roles of mast cells 












激活作用；另外，我們也硏究Toll樣受體（Toll like receptor, T L R )在人類 
肥大細胞系HMC-1中的表達，及HMC-1對於其配體的免疫反應。透過使 
用流式細胞小球微陣列術（cy tomet r ic beads a r r a y )及酶聯免疫法 
(ELISA)，我們測定了嗜酸性粒細胞在chymase的作用下，釋放趨化因子 
(chemokines)及炎症因子（inflammatory cytokine)的改變。而細胞表面f占附 






CXCL1，CXCL8，CCL2 及 inflammatory cytokine 白介素（interleukin)-6� 
而上述因子的釋放程度依頼於chymase的濃度。Chymase亦能上調細胞表面 
黏附分子C D 18的表達，減少細胞凋零情況及提高嗜酸性粒細胞的移動能 
力。以上作用牽涉的細胞內信號傳導包括p38絲裂原激活的蛋白激酶（p38 
mitogen-activated protein kinase)途徑，細胞外信號調節激酶（extracellular 
signal-regulated kinases, ERK)途徑，STAT3 信號轉導通路 JAK-酶途徑’ 
PBK/Akt途徑及胞核因子（nuclear factor)-KB途徑。 
在第二部份，HMCM細胞系在蛋白層面表達了 TLR1, TLR2, TLR3, TLR5, 
TLR6, TLR7及TLR9�但只有TLR7的配體Imiquimoid能提高HMC-1細胞 
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Chapter 1 Introduction 
Chapter 1 
General Introduction 
1.1 Allergic Diseases and Allergic Inflammation 
1.1.1 Prevalence of Allergic Diseases 
In 2004, the World Allergy Organization's Specialty and Training Council 
conducted a worldwide survey to obtain information about the status of the 
specialty of allergy. The survey, answered by 33 countries and amounting 1.39 
billion people, reported that 22 % of the population suffers from some forms of 
allergic diseases (Warner et al, 2006). The burden of these diseases to 
governments, healthcare systems, families and patients is in increasing trend 
worldwide. In Hong Kong, the atopic rate of current wheeze, rhinoconjunctivitis 
or flexural dermatitis is even as high as 41.2 % (Wong et a/., 2001). It is much 
more common than the nearby cities such as Beijing (23.9 %) and Guangzhou 
(30.8 o/o) (Wong et al, 2001). 
1.1.2 Common Allergic Diseases: Allergic Asthma 
It is estimated that as many as 300 million people of all ages and all ethnic 
backgrounds are suffering from asthma (Masoli et aL, 2004). In Hong Kong, 
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more than one-tenth of the school children aged 13 to 14 were diagnosed with 
asthma (Wong et al., 2004). 
Asthma is a chronic inflammatory disorder of the respiratory system, in 
which the airway is constricted occasionally due to exposure to one or more 
environmental stimulants (Tillie-Leblond et al,, 2005). For children, viral 
respiratory infection is associated with asthma exacerbation (Zhao et al., 2002). 
The underlying mechanism of asthma is complicated and it is not yet fully 
understood nowadays. However, imbalance of Thl and Th2 lymphocytes, 
elevated serum IgE concentration and family history of allergic diseases have 
been suggested to be potential risk factors (Glezen et al” 2006). 
1.1.3 Common Allergic Diseases: Allergic Dermatitis (AD) 
Among Hong Kong school age children, it is estimated that nearly 20 % of 
them are affected by AD (Wong et al” 2001). AD is a chronic and relapsing 
disorder characterized by superficial skin inflammation. Typical symptoms 
include intense pruritus and unsightly lesions, formation of pale, erythematous 
hues, vesiculation, exudation, crusting and lichenification on skin (Ong & Leung, 
2006). In AD patients, minor skin stimulation is perceived as an itch. When the 
2 
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skin lesion is scratched or rubbed, a heightened immune response is induced. 
Although the cause of AD is still unknown, it is suggested that both genetic 
predisposal (family history of AD, asthma and rhinitis) and environmental 
factors (live at higher latitudes) contribute to the disease's progression (Miraglia 
del Giudice et al, 2006). 
1.1.4 Allergic Inflammation 
Allergic inflammation is the common pathophysiological feature of allergic 
diseases including allergic asthma, AD and allergic rhinitis. By understanding the 
underlying immunological events, a framework could be constructed to delineate 
the development of symptoms, which varies diversely between diseases (Leung, 
2000; Gelfand, 2004). 
The progression of allergic inflammation could be briefly divided into two 
phases with mast cells as the central effector cell: the immediate hypersensitivity 
(early phase), and the late phase reaction (Figure 1.1). The early phase of the 
allergic reaction typically occurs within minutes (min), or even seconds (sec). It 
is often triggered by exposure of antigens with Ig-E mediated mast cell 
degranulation. The following late phase reaction takes further 6 - 1 2 hours (h) to 
3 
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develop leukocyte recruitment, release cytotoxic molecules, produce excessive 
IgE and bias to Th2 (Roitt & Delves, 2001). 
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Figure 1.1 Schematic diagram of mast cell-mediated allergic inflammation. The 
binding of allergen-binding IgE to IgE receptor on mast cell surface triggers 
degranulation, which could mediate early phase, late phase and chronic allergic 
inflammation. (Modified from Pawankar, 2005) 
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1.2 The Inflammatory Leukocytes: Mast Cells and Eosinophils 
1.2.1 Characteristics of Mast Cells 
Mast cells were first described by Paul Ehrlich in 1878. The densely packed 
cytoplasmic granules led him to the mistaken belief that they existed to nourish 
the surrounding tissues. Therefore he named them "mastzellen", meaning 
"feeding cells". Nowadays, it is found that mast cells are far more versatile in 
both immunity and physiology (Vliagoftis & Befus, 2005). As mast cells are 
heavily granulated, their sizes are large and vary from 5 to 30 ^m in diameter 
(normal T-lymphocyte 6-10 jLim) (Prussin et cd, 2006). 
Mast cells play an important role in both initiation and progression of allergic 
inflammation. Upon the stimulation by exogenous allergens or antigens, mast 
cells could release stored mediators or synthesize immediately (Prussin et al, 
2006). Besides the well-known histamine, cytokines and chemokines, neutral 
proteases and lipid metabolites are produced by mast cells (Henz et al., 2001). 
Mast cell accumulation at inflamed sites could also be achieved by modulating 
the expression of cell surface adhesion molecules so as to intensify the 
inflammatory response (Henz et a!.，2001) (Figure 1.2). 
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Figure 1.2 Mast cell surface adhesion molecules and mediators. The schematic 
diagram illustrates surface adhesion molecules and mediators expressed by 
human mast cells. (Modified from Henz et a/., 2001) 
7 
Chapter 1 Introduction 
1.2.2 Mast Cells Distribution 
Mast cells are derived form CD34+ heamatopoietic progenitor cells in bone 
marrow. However, they only undergo maturation in tissue with the stimulation of 
growth factor such as stem cell factor (SCF). Mast cells are strategically located 
at the interface between environment and internal body, including the 
perivascular spaces and connective tissues of the respiratory and gastrointestinal 
system, as well as beneath the skin (Sellge et al., 2006). 
In lungs, mast cells are found in both bronchial airway connective tissues and 
peripheral intra-alveolar spaces. In skin, mast cells appear in the greatest number 
near blood vessels, hair follicles, sebaceous glands and sweat glands (Henz et al., 
2001). 
1.2.3 Mast Cells Subtypes 
Classification of mast cell subtypes are based on their expression of neutral 
proteases chymase and tryptase (Beil & Pammer, 2001; Forsythe & Ennis, 2000). 
Mast cells in human lung parenchyma and intestinal mucosa predominantly 
contain tryptase only (MCj) whereas mast cells in the skin and intestinal 
submucosa contain both tryptase and chymase (MCTC) (Beil & Pammer, 2001; 
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Forsythe & Ennis, 2000). These two subtypes of human mast cells demonstrate 
varying responses to different activating stimuli and pharmacological modulators 
of mast cell activation (Forsythe & Ennis, 2000; Krishnaswamy et al., 2001). 
Furthermore, mast cells produce only chymase (MCc) could be raised from bone 
marrow and umbilical cord blood progenitors cells in vitro with the supply of 
growth factors (Li et al., 1996). MCc was not yet found in primary tissue and 
little study was received on this subtype to date. 
1.2.4 HMC-1 cells 
Mast cells are tissue resident cells therefore they are not normally found in 
blood circulation. Isolation of mature mast cells from tissues is tedious and is 
very difficult to ensure the purity (Wang & Lau, 2007). Besides, raising mast 
cells from CD34+ progenitor cells is time-consuming and expensive as 
supplement of growth factors is needed for at least six weeks (Wang & Lau, 
2007). Therefore, human mast cell lines are commonly used as an in vitro model 
for mast cell study. 
HMC-1 cells are the mast cell line established from the peripheral blood of 
patient with mast cell leukemia (Figure 1.3). It shares many characteristics of 
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mast cells such as the expression of SCF receptor (c-kit) and high affinity IgE 
receptor (FCBRI), production of inflammatory mediators such as histamine, 
tryptase, leukotrienes and prostaglandins (Butterfield et al, 1998; Welker et al., 
2001). For adhesion molecules, HMC-1 cells could express ICAM-1 and 
ICAM-3 (Tsang et al, 2005; Barbina et al., 2001; Weber et al” 1997). HMC-1 
cells are therefore convenient to researchers as no specific growth factor is 
needed in cell culture (Butterfield et al, 1998). 
10 
Chapter 1 Introduction 
‘ j f | p P 一 s 暴 . 
趣 • ： 
f - l i l i ^ � ill 4 
Figure 1.3 Photograph of HMC-1 cells under light microscope. HMC-1 cells 
were stained with hematoxylin for 10 min on a microscopic slide. (Magnification 
power: 400) 
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1.2.5 Characteristic of Eosinophils 
Eosinophils typically exhibit a bilobed nucleus with highly condensed 
chromatin and cytoplasm (Figure 1.4). They contain specific granules that 
consist of cationic proteins that make eosinophils a unique orange staining 
property by eosin. Primary granules in cytoplasm are similar to those found in 
other granulocyte lineages which contain numerous cytokines and chemokines 
(Prussin et al., 2006). Eosinophils are developed and terminally differentiated in 
the bone marrow from the CD34+ progenitor cells. Once released from the bone 
marrow, eosinophils circulate in the peripheral blood and then migrate to tissue. 
Normally, the lifespan of circulating eosinophils is between 8 - 18 h (Prussin et 
al., 2006). However, tissue eosinophils under chemokine stimulation could 
survive up to four days (Shinagawa et al., 2003). 
Eosinophils show the capacity to produce a number of mediators (Kita, 1996) 
(Figure 1.5). These mediators could exert proinflammatory effects by regulating 
vascular permeability, enhancing mucus secretion and inducing smooth muscle 
contraction (Rothenberg & Hogan, 2006). Surface adhesion molecule expression 
pattern of eosinophils could also be modulated to enhance their migratory 
behavior to inflamed sites (Gleich et al, 1986). 
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Figure 1.4 Photograph of eosinophils under light microscope. Eosinophils 
isolated from human buffy coat were stained with hematoxylin for 10 min on a 
microscopic slide. (Magnification power: 400) 
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Figure 1.5 Eosinophils surface adhesion molecules and mediators. This 
schematic diagram illustrates surface adhesion molecules and mediators 
expressed by eosinophils. (Modified from Rothenberg & Hogan, 2006) 
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1.3 Adhesion Molecules in Allergic Diseases 
1.3.1 Adhesion Molecules and Leukocyte Migration 
The interactions of leukocytes with the vessel endothelium facilitate 
leukocyte extravasations. However, excessive recruitment of leukocytes into the 
inflamed tissue could cause adverse allergic condition (Roitt & Delves, 2001) 
The multi-step process of leukocyte rolling, firm adhesion and transmigration 
through the endothelial wall is facilitated by a dynamic interplay of adhesion 
receptors on leukocytes and endothelial cells, as well as chemokines (Rosenberg 
et al., 2007). The adhesion molecules selectins, integrins and intermolecular 
adhesion molecules are the key players for the transmigration process on 
leukocytes (Figure 1.6) (Rosenberg et al., 2007). 
15 
Chapter 1 Introduction 
Endothelial cell — 
•^一 - 、、、 - — 一 ‘ 一 - - v ^ 〜 ^� 
•、〜 ^^ ^^ ^^ ^ "‘ 一&一 ~ 
Tethering Rolling Firm Transmigration 
Eosinopi^ , 泌 . Adhesion 
B l o o d F l o w J 旧 产 r v 
^ / 一— lyi^d — — ^ ^ ^ 
/ tr • I 
Adhesion ^ ^ ^ ^—、—^ ^—y—^ • I ^ 
Molecules Selectins Integrins ICAMs • • I 1 1 
• • • 墨 i 专 
Figure 1.6 Leukocyte transmigration. Eosinophils as an example of leukocytes in 
demonstrating the migration from blood circulation to inflamed tissue. Selectins 
and their ligands present on eosinophils and the vascular endothelium promote 
initial tethering and rolling of eosinophils. Integrins mediate eosinophil 
activation and adhesion while intermolecule adhesion molecules (ICAM) 
facilitate the migration through the endothelium in a direction determined by 
chemokine gradients. (Modified from Rosenberg et al., 2007) 
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1.3.2 Selectin 
Selectins are family of three related glycoprotein whose function is to 
mediate leukocyte rolling process through recognition of cell surface 
carbohydrate-based ligands (Springer, 1994). It included CD62L (L-selectin), 
CD62P (P-selectin) and CD62L (L-selectin). Only CD62L is expressed on 
leukocytes while CD62E and CD62P are expressed on activated endothelium and 
platelets. Shedding of CD62L from leukocytes is highly regulated to act as 
endogenous mechanism for the down-regulation of inflammation (Strausbaugh et 
al., 1999). 
1.3.3 Intercellular Adhesion Molecules (ICAM) 
ICAM belong to the Immunoglobulin (Ig) superfamily, which is a large 
group of cell surface and soluble proteins involved in the recognition, binding 
and adhesion processes of cells. ICAM family includes ICAM-1, ICAM-2， 
ICAM-3 and vascular cell adhesion molecule (VCAM)-l, all of them are 
responsible for cellular adhesion (Roitt & Delves, 2001). 
ICAM-1 is a surface glycoprotein with five Ig-like domains, which is 
constitutively expressed on various leukocytes such as eosinophils and mast cells 
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(Tsang et al.，2005; Cheung et al., 2006). Upon inflammatory cytokine activation 
such as tumor necrosis factor (TNF)-a and IL-13, surface expressions in mast 
cell were largely increased (Tsang et al., 2005). This molecule is constitutively 
expressed on endothelial cells and most leukocytes (Sawa et al., 2007; Lebedeva 
et al.，2005). Ligands of ICAM-1 are (32 integrin LFA-1 and DC-SIGN (Montoya 
et al, 2002). 
ICAM-2 has 35% homology to ICAM-1 with a shorter cytoplasmic tail 
(Huang et al., 2006). ICAM-2 appears in vitro to be more concentrated at 
endothelial cell junctions. Limited studies have been worked on the role of 
ICAM-2 in transmigration process (Huang et al, 2006). 
ICAM-3 is constitutively expressed at high levels on leukocytes such as 
eosinophils and mast cells (Cheung et al., 2006; Barbina et al., 1997). Ligands of 
ICAM-3 are (32 integrin LFA-1 and DC-SIGN (Montoya et al., 2002). VCAM-1 
is only expressed on endothelial cells but not on leukocytes (Bevilacqua, 1993). 
1.3.4 Integrin 
Integrins are heterodimeric protein composed of a and P subunits. Up-to-date, 
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18a and 8|3 subunits have been identified and assembled to 24 distinct integrins 
with specific and non-redundancy functions (Hynes, 2002). 
The largest integrin family composed of the (31 subunit. Their expressions 
are widespread in various cells (Roitt & Delves, 2001). Binding of their 
respective ligands such as fibronectin, collagen and laminin can facilitate 
adhesion of leukocytes at the matrix of tissue. Members of the p2 integrin (also 
known as CD 18) subfamily are expressed in most leukocytes. Major ligands are 
the immunoglobulin superfamily molecules such as ICAM which are expressed 
on endothelial cells to allow attachment of leukocytes to the vessel wall (Roitt & 
Delves, 2001). 
Apart from the transmigration process, integrin serves to modulate many 
aspects of cellular behavior including proliferation，survival, shape, polarity, 
motility, gene expression, signal transduction and differentiation (Hynes, 2002). 
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1.4 Cytokines and Chemokines in Allergic Diseases 
1.4.1 IL-6 
IL-6 is a proinflammatory Th2 cytokine produced by various cell types, such 
as T-lymphocytes, B-lymphocytes, monocytes, fibroblasts, keratinocytes and 
endothelial cells (Nishimoto et al., 2006). Increased production can be mediated 
by other Th2 cytokines, such as IL-4 and IL-25 (Alexis et al, 2002; Wong et al., 
2005). 
IL-6 was originally identified as a T-cell-derived B-cell differentiation factor, 
as it induced B-lymphocytes to differentiate into antibody-producing cells 
(Oshizaki et al., 1984). It can mediate acute inflammatory by inducing the 
production of acute phase proteins such as C-reactive protein and fibrinogen 
(Kopfet al., 1994; Kishimoto, 2005). 
In modulating allergic diseases, IL-6 enhances angiogenesis by promoting 
vascular endothelial growth factor (VEGF) production (Nakahara et al., 2003). 
Upon allergen challenges such as house dust mite, the IL-6 production was 
significantly increased in the coculture system of eosinophils and epithelial ceils 
(Wong et al., 2006; Wang et al., 2005). In chronic sinusitis patients, IL-6 mRNA 
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expression were significantly greater in allergic patients when compared to 
normal (Ghaffar et al, 1998) 
1.4.2 CXCLl (Growth-related Oncogene-a) 
CXCLl is produced by eosinophils, macrophages, endothelial cells, 
fibroblasts and smooth muscle cells after the stimulation of IL-1 and TNF (Lin et 
al., 2007; Wong et al, 2007; Taubert et al., 2007; Issa et al., 2006; Eck et al., 
2000). It is a powerful activator of neutrophils on chemotaxis and exocytosis in 
vitro, neutrophil accumulation in vivo (Geiser et al” 1993). 
CXCLl is a primary chemoattractant of neutrophils in chronic rhinosinusisits 
(Rudack et al., 2006) and correlated to the severity of inflammatory bowel 
disease (Mitsuyama et al” 2006) 
1.4.3 CXCL8 (IL-8) 
CXCL8 is both an inflammatory cytokine and CXC chemokine in human. It 
can be produced and released by a variety of cells such as leukocytes (monocytes, 
macrophages, mast cells, T-lymphocytes) and structure cells (endothelial cells, 
fibroblast and bronchial epithelial cells) (Scaife et al., 2006; Tamai et al” 2002; 
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Ameixa et al., 2002; Resto-Ruiz et al., 2002). The receptor of CXCL8 is 
heterodimeric (CD128, composed of CXCRl and CXCR2) and it is highly 
expressed on neutrophils (Pease & Sabroe, 2002). 
CXCL8 is chemotaxtic to neutrophils, eosinophils and lymphocytes in vitro 
(Salamon et al” 2005; Gordon et al, 2003; Schratzberger et al, 1997). On 
neutrophils, CXCL8 could enhance transmigration through basement membrane, 
mobilization of intracellular calcium and release of leukotriene B4 (LTB4) 
(Bochenska-Marciniak et al., 2003; Izumi et al” 2006). 
In asthma patients, CXCL8 concentration was elevated in their 
bronchoalveolar lavage fluids and sera (Tillie-Leblond et al” 2005). Mold 
allergen and bacteria proteins could also stimulate the production of CXCL8 in 
airway epithelial cells, which may imply the role of CXCL8 in allergic asthma 
pathogenesis (Chiu et al., 2007; O'Brien et al., 2006). 
1.4.4 CCL2 (Monocyte Chemotactic Protein-1) 
CCL2 is a CC chemokine and proinflammatory cytokine produced by a 
variety of cells upon cytokine stimulation [such as IL-1, TNF-a and interferon 
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(IFN)-y], bacterial and viral products or mitogens (Rollins, 2001). Leukocytes 
such as monocytes and T-lymphocytes could express the CCL2 receptor CCR2 
and exert chemotactic effect on them (Marra, 2005). 
CCL2 secretion is enhanced during inflammation and infection, both are 
characterized by leukocytes infiltration (Fujiyama et al, 2003). Other biological 
functions involved facilitating monocyte adhesion to endothelial cells (Fujiyama 
et al, 2003), inducing macrophage to release nitric oxide (Brandonisio et al.’ 
2002), synthesizing collagen by fibroblasts (Gharaee-Kermani et al” 1996), 
inducing mast cell degranulation and aggregation (Conti et al., 1995) and 
regulating the surface expression of adhesion molecule (Vaddi & Newton, 1994) 
In animal models of allergic asthma, idiopathic pulmonary fibrosis, and 
bronchiolitis obliterans syndrome, CCL2 expression and protein production were 
increased and the disease process is attenuated by CCL2 immunoneutralization 
(Rose et al, 2003). 
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1.5 Intracellular Signal Transduction Pathways in Inflammation 
1.5.1 RAS-RAF-mitogen-activated Protein Kinases (MAPK) Pathway 
The MAPK cascade is a crucial pathway in mediating inflammatory 
responses, which involved three important members in mammalian cells~the 
extracellular signal-regulated protein kinases (ERK), the p38 MAPK and the 
c-Jun N-terminal kinases (INK) (Figure 1.7, Table 1.1). The MAPK pathways 
are activated by dual phosphorylation on Threonine (Thr) and Tyrosine (Tyr) at 
the tripeptide motif Thr-X-Tyr with different intervening amino acid X (Dong et 
al., 2002). Activation of the MAPK cascade is rapid and enables cells to respond 
to environmental changes in a prompt and regulated fashion (Arbabi & Meiar, 
2002). 
The role of MAPK in immune response has been intensively studied. In 
innate immune response, p38 MAPK was involved in mediating IL-12 
production in macrophages and dendritic cells; p38 MAPK and JNK were 
involved in inflammatory cytokine response (IL-la, IL- ip and IL-6 and TNF-a); 
ERK, JNK and p38 MAPK were involved in T cell activation and lymphocyte 
apoptosis (Dong et al., 2002). 
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Figure 1.7 The MAPK pathway. The MAPK cascade consists of three sequential 
intracellular protein kinases activation. The first member MAPK kinase kinase 
(MAPKKK) phosphorylate MAPK kinase (MAPKK). Subsequently, MAPKK 
activates MAPK, and the phosphorylated MAPK activates other protein kinases, 
nuclear proteins, or transcription factors to activate inflammatory gene 
transcription at nucleus. (Modified from Dong et al., 2002) 
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Target Mode of Action Chemical 
Inhibitor 
MAPK Structure 
^ Competitive inhibitor of ATP Pyridinyl 
SB203580 p38 MAPK ^ 
binding site of p38 MAPK imidazole 
Non-competitive inhibitor of Flavone 
PD98059 ERK ^ 
ERK compound 
SP6000125 JNK Competitive inhibitor of ATP Anthrapyrazolone 
binding of JNK compound 
Table 1.1 Specific inhibitors for studying the MAPK pathway. Synthetic 
compound SB203580, PD98059 and SP6000125 are selective inhibitors for p38 
MAPK, ERK and JNK respectively. (Arbabi & Meiar, 2002) 
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1.5.2 Janus Kinase (JAK)-Signal Transducers and Activators of 
Transcriptions (STAT) Pathway 
In mammals, three JAKs have been identified including JAKl, JAK2 and 
JAK3 (Imada & Leonard, 2000). The JAK-STAT signaling pathway could 
regulate the production of more than 50 cytokines or growth factors which has 
been implicated in a variety of cellular functions in the hematopoietic, immune, 
neuronal and hepatic systems (Imada & Leonard, 2000). The JAK-STAT 
pathway is important in growth and maturation of lymphoid cells and mediates 
anti-viral activity (O'sullivan et al., 2007). 
Activation of JAK-STAT pathway is triggered by the ligand binding of 
receptor which have specific JAK docking domain at the cytoplasmic side 
(O'sullivan et al, 2007) (Figure 1.8). When ligand binds to cognate receptor, the 
receptor-associated JAK and cytoplasmic STAT are activated successively and 
lead to a rapid signaling from the cell surface to the nucleus (Imada & Leonard, 
2000). 
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Figure 1.8 The JAK/STAT pathway. Activator bind to receptor on the cell surface 
and ligation induces receptor dimerization. This receptor-kinase complex 
activates cytoplasmic transcription factor STAT (including STATl, 2, 3, 4，5, 6). 
The phosphorylated STATs forms a dimer and translocates to the nucleus to 
activate the transcription of target gene. AG490 is a JAK inhibitor to prevent 
phosphorylation of STAT. (Modified from O'Neill et aL, 2006) 
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1.5.3 Nuclear Factor (NF)-KB Pathway 
N F - K B was first identified as a nuclear factor in B-lymphoctes. Nowadays, 
N F - K B is found to be present in virtually every cell type (Inoue et al., 2007). 
N F - K B is a heterogeneous collection of dimmers (Inoue et al., 2007). In an 
unstimulated cell, NF-KB is bound to IKB and is retained in the cytoplasm as an 
inactive form (Baldwin, 1996) (Figure 1.9). 
N F - K B pathway is involved in the Th2 cytokine IL-25 and inflammatory 
cytokine IL-6-mediated response in releasing inflammatory cytokines and 
upregulating adhesion molecules (Wang et al., 2005; Wong et al” 2005; Cheung 
et al., 2006). Synthetic NF-KB pathway inhibitor is also recently found effective 
in alleviating AD symptoms and reducing airway inflammation (Tanaka et al., 
2007; El Bakkouri et a!., 2005). 
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Figure 1.9 The N F - K B Pathway. Proinflammatory signal induces N F - K B 
activation pathway by degrading IKB-CX，one of the six members in the 
IKB family. IICB-a is phosphorylated by IKB kinase (IKK) and is degraded in 
proteasome to release N F - K B . Later, N F - K B is translocated into nucleus and 
becomes active in DNA-binding. The IKK selective inhibitor BAYl 17082 could 
prevent the phosphorylation of IKB-a (Karin & Ben-Neriah, 2000). (Modified 
from Inoue et al., 2007) 
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1.5.4 Phosphoinositide 3-kinases (PI3K) Pathway 
PI3K catalyzes the transfer of the Q-phosphate group of ATP to the D3 
position of phosphoinositides together with activating Akt (as known as protein 
kinase B) by phosphorylation (Wymann & Piorla, 1998). Akt is an important 
relay to control metabolic activity, growth and proliferation in leukocytes 
(Wymann & Pirola, 1998). (Figure 1.10) 
Akt has been shown to play multiple roles in cellular regulation such as 
glycogen synthesis, cell cycle, cell growth, cell survival, and protein synthesis 
(Franke et al., 1997). 
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Figure 1.10 The PI3K pathway. Activated PI3K recruits and phosphorylates Akt. 
Akt could subsequently activate transcription factor such as AP-1 to upregulate 
the transcription of inflammatory cytokines. Inhibitor LY294002 could inhibit 
the activity of PI3K so as to halt the signal transduction cascade. (Modified from 
Hawkins, 2006) 
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1.6 Aims and Scope of the Study 
Mast cell is a versatile leukocyte in initiating instant inflammatory response 
when challenged by invaders. However, hypersensitivity to stimulation leads to 
pathological condition such as allergy. In this study, the roles of mast cells in 
mediating allergic inflammation were investigated. 
Mast cells could produce lots of mediators while activated. Two serine 
proteases, chymase and tryptase are produced in addition to the array of 
cytokines and their secretion pattern is thought to be related to different allergic 
diseases. Particularly in asthma and allergic dermatitis, elevated serum 
concentrations of chymase were reported (Morar et al., 2006; Bradding et al, 
2006). To elucidate the details of allergic disease pathogenesis, the effects of 
human chymase on human eosinophils were investigated by studying the cell 
viability, expression of adhesion molecules, secretion of cytokines and 
chemokines. Eosinophils are important leukocytes in the late-phase allergic 
disease progression in AD (Leung, 2000). And accumulation and activation of 
eosinophils are well-known in many allergic inflammatory conditions 
(Rosenberg et al., 2007). 
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On the other hand, Toll-like receptors (TLR) are newly discovered innate 
receptors and their roles in mediating innate immunity and allergic condition 
were intensively studied recently. However, very limited studies have been 
worked on human mast cells. In this study, the expression of TLR and their 
effects to their responsive ligands were investigated. Both cytokine releases and 
adhesion molecule expressions were measured by flow cytometry and protein 
array. 
To further understand the underlying signaling mechanisms in regulating the 
responses of chymase on eosinophils and TLR ligands on human mast cells, 
selective signaling pathway inhibitors PD98059, SB203580, BAYl 17082, 
SP6000125, AG490 and LY294002 were used to elucidate the responsible 
signaling pathway. Western blot analysis was also applied to measure the 
phosphorylation status of key signaling molecules in each pathway. In 
understanding the intracellular signaling mechanism, we hope to generate 
pharmacological implication for treating inflammatory diseases. 
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Chapter 2 
Materials and Methods 
2.1 Materials 
2.1.1 HMC-1 Cell Line 
HMC-1 cells were a generous gift from Dr J H Butterfield of the Mayo 
Clinic, Rochester, MN, USA. It is a human mast cell line established from the 
peripheral blood of a patient with mast cell leukemia (Butterfield et al., 1988). 
2.1.2 Human Bufly Coat 
Human Buffy coat was obtained from the Hong Kong Red Cross Blood 
Transfusion Service. Eosinophils were purified from buffy coat within 24 h after 
donation. 
2.1.3 Human Mast Cell Chymase and TLR Ligands 
Chymase from human skin mast cells was purchased from Sigma-Aldrich Co, St. 
Louis, MO, USA. Ultrapurified lipopolysaccharide (LPS) from E.Coli K12 strain 
without any contamination by lipoprotein, R837 (Imiquimod, a synthetic 
antiviral molecule), ssRNA and CpG DNA, for TLR4, 7, 8 and 9 were purchased 
35 
Chapter 2 Materials and Methods 
from InvivoGen Corp, CA, USA, while flagellin for TLR5 was from Calbiochem 
Corp, CA, USA. Poly IC (TLR3 ligand) was purchased from Sigma-Aldrich Co 
and peptidoglycan (PGN) for TLR2 from Fluka Chemie GmbH, Switzerland. 
2.1.4 Media and Reagents for Cell Culture 
(1) Culture Medium 
Roswell Park Memorial Institute (RPMI) 1640 Medium and Iscove丨s 
Modified Dulbecco's Medium (IMDM) containing 25 mM 
N-2-hydroxy-ethyl-piperazine-N'-2-ethane-sulfonic acid (HEPES) and 2 mM 
L-glutamine at pH 7.2 were used to culture eosinophils and HMC-1 cells 
respectively. The following culture media were purchased from Invitrogen Corp, 
Carlsbad, CA, USA. 
(2) Serum Supplements 
Fetal calf serum (FCS) was purchased from Invitrogen Corp. It had been 
tested with low endotoxin (<10 EU/ml) and hemoglobin (<10 mg/ml) level. 
Heat-inactivated FCS (HI-FCS) was prepared as 50 ml aliquots by heating at 
56 OC for 30 min and stored at -20 until use. 
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2.1.5 Reagents and Buffers for Purification of Human Eosinophils 
(1) Sodium Chloride (NaCl) Solution (1.5 M) 
NaCl (1.5 M) solution was prepared by dissolving 87.6 g NaCl 
(Sigma-Aldrich Co) in double distilled water (one litre) and sterilized by 
autoclaving at 121 for 15 min. The concentrated stock solution was further 
diluted to 1.8 % (w/v) and 0.9 % (w/v) sterile normal saline. The solutions were 
kept at 4 
(2) Percoll Solution (1.082 g/ml) 
Percoll solution (150 ml, density 1.082 g/ml) was freshly prepared by mixing 
87.92 ml Percoll stock solution (density 1.130 g/ml, Amersham Biosciences, 
Piscataway, NJ, USA), 15 ml sterilized NaCl (1.5 M) and 47.1 ml sterilized 
double distilled water in the culture hood. 
(3) Magnetic Cell Sorting System (MACS) and Anti-CD 16 Magnetic Micro 
Beads 
The MACS and anti-CD 16 magnetic micro beads were purchased from 
Miltenyi Biotec Inc, Bergisch Gladbach，Germany. The MACS consists of a 
MidiMACS Separation Unit, a MACS MultiStand and a LS Separation Column 
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which can separate maximum of 2 x 10^  total cells and 10^  magnetically labeled 
cells. The anti-CD 16 magnetic micro beads which were super-paramagnetic 
microbeads conjugated to monoclonal mouse anti-human CD 16 antibodies. They 
were used for isolation of untouched eosinophils from peripheral blood by 
depletion of CD 16 positive neutrophils. 
(4) Wash Buffer 
Sterilized Phosphate buffer saline (PBS, Sigma-Aldrich Co) was 
supplemented with HI-FCS (2 %) was served as washing buffer in MACS and 
were kept at 4 
2.1.6 Reagents and Buffers for Flow Cytometer 
(1) FACSFlow Sheath Fluid 
The sheath fluid is a ready-to-use product purchased from BD Biosciences, 
San Jose, CA, USA. It is a balanced electrolyte solution containing sodium 
chloride, potassium chloride, disodium ethylenediaminetetraacetates (EDTA), 
sodium fluoride and anti-microbial agent. The solution was kept at room 
temperature. 
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(2) FACS Staining Medium 
The buffer contained 0.5 % HI-FCS and 0.01 % sodium azide (NaNs) in PBS 
(Sigma-Aldrich Co). It was kept at 4 and also used for washing in 
immunofluorescent staining. 
(3) Paraformaldehyde (1 %) in PBS for Cell Fixation 
Paraformaldehyde powder (10 g) purchased from Sigma-Aldrich Co was 
dissolved in PBS (one litre). It was titrated to pH 7.4 and kept at 4 until use. 
(4) Annexin V-Fluorescein isothiocyanate (FITC)/ Propidium Iodide (PI) 
Apoptosis-Detection Kit 
TAGS™ Annexin V-FITC/ PI staining kit was purchased from Trevigen Inc, 
Gaithersburg, MD, USA. It was used for quick detection of apoptotic cells. It 
consisted of a lOX annexin V binding buffer, PI DNA staining buffer (50 |Lig/ml), 
and lOOX annexin V-FITC conjugate. The kit was stored at 4 
(5) BDTM CBA Human Soluble Protein Flex Set 
BDTM CBA Human Soluble Protein Flex Set for the measurement of IL-6, 
CXCL8 and CCL2 concentration were purchased from BD Biosciences and 
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Stored at 4 The detection limit of IL-6, CXCL8 and CCL2 are 0.2 pg/ml, 
2.4 pg/ml and 1.3 pg/ml, respectively. 
(6) Monoclonal Antibodies for Immunofluorescent Staining 
a. FITC-conjugated mouse IgG! anti-human ICAM-1 (CD54) monoclonal 
antibody 
Antibody (clone BBIG-Il) was purchased from R&D Systems Inc. It was 
used in direct immunofluorescent staining with 4 |li1 per 5x10^ cells. 
b. FITC-conjugated mouse IgG2b anti-human ICAM-3 (CD50) monoclonal 
antibody 
The antibody (clone TU41) from BD Biosciences was buffered in PBS 
(pH 7.4) with 0.09 % (w/v) NaNs and 0.2 % (w/v) bovine serum albumin 
(BSA). It was used in direct immunofluorescent staining with 8 \i\ per 
5 X 10^  cells. 
c. FITC-conjugated mouse IgGi anti-human CD 18 monoclonal antibody 
The antibody (clone 6.7) from BD Biosciences was kept in buffered 
solution containing BSA and 0.09 % (w/v) NaNs. It was used in direct 
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immunofluorescent staining with 8 ]x\ per 5x10^ cells. 
d. FITC- conjugated mouse IgGi anti-human CD62L monoclonal antibody 
The antibody (clone Dreg 56) from BD Biosciences was kept in buffered 
solution containing BSA and 0.09 % (w/v) NaNs. It was used in direct 
immunofluorescent staining with 8 |LI1 per 5x10^ cells. 
e. FITC-conjugated mouse IgG] monoclonal immunoglobulin isotype control 
The antibody (clone MOPC-21) purchased from BD Biosciences, was 
buffered in PBS (pH 7.4) with 0.09 % (w/v) NaNs and 0.2 % (w/v) BSA. It 
was used as an isotypic control in direct immunofluorescent staining with 
8 fil per 5x10^ cells. 
(7) Human Serum 
Human serum was obtained from venous blood of Chinese healthy 
volunteers and for blocking procedure in immunofluorescent staining. 
2.1.7 Reagents and Buffers for Total RNA Extraction 
The Qiagen R N e a s y � Total RNA Extraction kit purchased from Qiagen 
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GmbH, Hilden, Germany, was used to extract RNA. It consisted of a guanidine 
isothiocyanate containing lysis buffer RLT for cytolysis, RNeasy spin columns 
for RNA capture, wash buffers RWl and RPE for RNA precipitation and 
washing, and RNase-free water for RNA elution. Each RNeasy spin column had 
a binding capacity of 100 |Lig. 
2.1.8 Reagents and Buffers for Reverse Transcription - Polymerase Chain 
Reaction (RT-PCR) 
(1) First-strand cDNA synthesis kit 
The kit was purchased from Amersham Biosciences and stored at -20 It 
consisted of the following components: 
a. Bulk First-Strand cDNA Reaction Mixes: Cloned, FPLCpure® Murine 
Reverse Transcriptase, RNAguard (porcine), RNase/DNase-Free BSA, 
dATP, dCTP，dGTP, and dTTP in aqueous buffer. 
b. DTT Solution: 200 mM aqueous solution. 
c. pd(N)6 Primer: Random hexadeoxynucleotides at 0.2 fig/fil. 
d. Not I-d(T)i8 Bifunctional Primer: 5, d[AAC TGG AAG AAT TCG CGG 
CCG CAG GAAT18]-3' at 5 fig/^il. 
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e. DEPC-treated RNase-Free Water 
(2) AmpliTaq Gold™ with GeneAmp® lOX PGR buffer and MgCb solution 
AmpliTaq Gold DNA polymerase (250 units, 5 U/^il), lOX PGR reaction buffer 
[100 m M Tris-HCl, pH 8.3, 500 mM KCl, 15 mM MgCb, 0.01 % (w/v) gelatin] 
and 25 m M MgCb solution were all from Perkin Elmer Corp, Massachusetts, 
CA, USA, and stored at -20 
(3)Tris-EDTA(TE) Buffer 
The TE buffer consisted of 10 mM Tris-HCl (pH 7.5) and 0.1 mM EDTA in 
distilled water. The solution was used for cDNA dilution and kept at room 
temperature. 
(4) Primers 
The PGR primers specific for different human genes were purchased from 
Invitrogen Corp. The lyophilized primers were reconstituted in TE buffer to 
obtain a stock at a concentration of 100 pmoles/)Lil. The stocks were aliquoted 
and kept at -20 The primer sequences, annealing temperatures, and their PCR 
product sizes were as follows: 
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(a) ICAM-1 
Sense: 5，-CGT GCC GCA CTG AAC TGG AC-3’ 
Anti-sense: 5'-CCT CAC ACT TCA CTG TCA CCT-3' 
Annealing temperature: 60 
PGR product size: 447-bp 
(b) ICAM-3 
Sense: 5'-AGT TCT TGC ACA GGA ACA GTA GC-3' 
Anti-sense: 5'-TGA AGA CGT ACA TTA AGG CCA GT-3' 
Annealing temperature: 60 
PGR product size: 380-bp 
(c) P-actin 
Sense: 5'-AGC GGG AAA TCG TGC GTG-3' 
Anti-sense: 5,-CAG GGTACATGG TGG TGC C-3' 
Annealing temperature: 60°C 
PGR product size: 300-bp 
(5) PGR nucleotide mix 
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It was a premixed solution containing sodium salts of dATP, dCTP, dGTP and 
dTTP, each at a concentration of 10 mM in water at pH 7.5. The mixture was 
purchased from Promega Corp and stored at -20 
2.1.9 Reagents and Buffer for Agarose Gel Electrophoresis 
(1) Ethidium Bromide Solution 
The solution (10 mg/ml) was purchased from Invitrogen Corp and used for 
agarose gel electrophoresis of nucleic acids. 
(2) Tris-Acetate-EDTA (TAE) Electrophoresis Buffer (lOX) 
TAE Buffer (lOX Ultra Pure) from Invitrogen Corp, contained 400 mM 
Tris-acetate and 10 mM EDTA at pH 8.3. It was diluted to IX TAE Buffer in 
agarose DNA electrophoresis. 
(3) DNA Ladder Marker 
DNA ladder (100 base pair) from Invitrogen Corp was buffered in TE Buffer 
at concentration of 1 fig/|_il. This reagent was ten-fold diluted with loading buffer 
and TE buffer, and 8 \x\ of the diluted DNA ladder was used per lane. 
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(4) Agarose Gel 
Agarose gels (2 % w/v) were prepared by dissolving 2 g agarose (Invitrogen 
Corp) in 100 ml IX TAE buffer by heating in microwave. The 2 % agarose gel 
was used for PGR products gel electrophoresis. 
2.1.10 Reagents and Buffers for Sodium Dodecyl Sulfate 
(SDS)-polyacrylamide Gel Electrophoresis (PAGE) 
(1)) Acrylamide Solution (30 % w/v) 
The 30 % acrylamide/ Bis solution (29:1) was purchased from Bio-Rad 
Laboratories, Hercules, CA, USA. It was light-protected and stored at 4 ^C. 
(2) Ammonium Persulfate (APS) Solution (10% w/v) 
This was prepared by dissolving 0.5 g APS (Sigma-Aldrich Co) in 5 ml 
double distilled water. The solution was kept in 500 |LI1 aliquots at -20 "C until 
use. 
(3) Tris-HCl Buffer (pH 7.5) 
Tris[hydroxylmethyl] amino methane (Tris) from Sigma-Aldrich Co was 
prepared as 1 M stock solution in DEPC-treated double distilled water. The 
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buffer was adjusted to pH 7.5 with hydrochloric acid (HCl), then autoclaved at 
1 2 1 � C for 15 min and stored at 4 
(4) Upper Buffer for Stacking Gel and Lower Buffer for Separating Gel 
The upper Buffer was a 0.5 M Tris-HCl buffer adjusted to pH 6.8 and the 
lower buffer a 1.5 M Tris-HCl buffer adjusted to pH 8.8. Both buffers were kept 
at 4 °C. 
(5) Sodium Dodecyl Sulfate (SDS) Solution (10 %) 
This was prepared by dissolving 10 g SDS (Sigma-Aldrich Co) in 100 ml 
double distilled water and kept at room temperature. 
(6) N,N,N ‘ ,N‘ -Tetra-methylethylenediamine (TEMED) 
TEMED (Sigma & Aldrich Co) was used to initiate the polymerization of 
SDS-polyacrylamide gel. It was stored at room temperature in darkness. 
(7) Tris-Glycine-SDS Electrophoresis Buffer (lOX) 
Tris-glycine-SDS electrophoresis buffer lOX concentrate containing 0.25 M 
Tris-HCl, pH 7.5, 1.92 M glycine and 1% SDS in double distilled water was 
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filtered by a 0.2 |im millipore filter and stored at 4 This concentrate was 
diluted fresh to IX working buffer solution for SDS-PAGE. 
2.1.11 Reagents and Buffers for Western Blot Analysis 
(1) Antibodies 
For TLR protein expression study, monoclonal antibodies of rabbit 
anti-human TLRl (clone GD2.F4), rabbit anti-human TLR5 (clone 
19D1885.2.1), rabbit anti-human TLR6 (clone 86B1153), mouse anti-human 
TLR8 (clone 44C143), mouse anti-human TLR9 (26C593) and polyclonal rabbit 
anti-human TLR7, were purchased from Imgenex Corp, San Diego, CA, USA. 
Monoclonal antibodies of mouse anti-human TLR2 (clone TL2.1), anti-human 
TLR3 (clone TLR3.7) and polyclonal rabbit anti-human TLR4 antibodies were 
purchased from eBioscience Corp, San Diego, CA, USA. 
For signaling study, the anti-human phosphorylated IKB, anti-human 
phosphorylated JAK2, anti-human phosphorylated Akt polyclonal antibodies 
were purchased from Cell Signaling Technology Inc, Danver, MA, USA. The 
anti-human phosphorylated p38 and anti-human phosphorylated ERK 1/2 
antibodies were purchased by BD Bioscience Corp. The anti-human total ERKl, 
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anti-human total ERK2, anti-human total p38, anti-human JAK2 and anti-human 
total IKB antibodies were purchased form Santa Cruz Biotech Inc, Santa Cruz, 
CA, USA. Horseradish peroxidase conjugated goat anti-rabbit Ig secondary 
antibody and goat anti-mouse secondary antibody were purchased from 
Amersham Biosciences. 
(2) Polyvinylidene Difluoride (PVDF) Western Blotting Membranes 
The microporous PVDF membrane (pore size: 0.45 fj.m) was purchased from 
Amersham Biosciences and stored at room temperature. 
(3) Tris-Glycine Buffer (lOX) 
Tris-glycine buffer lOX concentrate consisted of 0.25 M Tris-HCl, pH 7.5 
and 1.92 M glycine in double distilled water. It was filtered by a 0.2 \im 
millipore filter and stored at 4 
(4) Tris-Glycine-Methanol Transfer Buffer ( IX) 
The transfer buffer was prepared by mixing 20 % methanol in IX 
Tris-glycine buffer and kept at 4 
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(5) Tris-Buffered Saline-Tween 20 (TEST) Washing Buffer 
This consisted of 10 mM Tris-HCl (pH 7.4), 150 mM sodium choloride and 
0.05 % (vol/vol) Tween 20 (Sigma-Aldrich Co). The solution was kept at 4°C. 
(6) Non-Fat Milk Blocking Solution (3 % w/v) 
Three gram non-fat milk powder (San Hua Co, Hong Kong, China) was 
freshly dissolved in 100 ml TBST washing buffer. The solution was used as a 
blocking solution. 
(7) Enhanced Chemiluminescent (ECL) Western Blotting Analysis System 
ECL detection kit was purchased from Amersham Biosciences. The kit was 
used for the detection of either mouse or rabbit membrane bound primary 
antibodies and stored at 4 
(8) ECL Films (Hyperfilm™ ECL™) 
The Hyperfilm ECL™ was a high performance chemiluminescence film 
used for Western blot analysis. It was purchased from Amersham Biosciencs. 
2.1.12 Chemotactic Migration 
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Boyden chamber and polycarbonate track-etch (PCTE) membrane with pore 
size 5 )Lim were purchased from Neuroprobe Inc, Gaithersburg, MD, USA. 
2.1.13 Signaling Transduction Inhibitors and Protein Synthesis Inhibitors 
All the inhibitors were purchased from Calbiochem, San Diego, CA, USA. 
PD98059 and SP600125 are selective inhibitors of ERK pathway and JNK 
pathway respectively. LY294002 is the selective inhibitor of PI3K pathway. 
BAY 117082 is the inhibitor of NF-KB pathway. AG490 is the inhibitor of 
JAK-STAT pathway. Actinomycin D and cycloheximide are RNA transcription 
inhibitor and mRNA translation inhibitor respectively. All the above inhibitors 
were dissolved in dimethy sulfoxide (DMSO). In all studies, the concentration of 
DMSO was 0.1 % (vol/vol). SB203580-HC1 is the inhibitor of p38 MAPK 
pathway, it was reconstituted in endotoxin-free water. All the inhibitors were 
stored at -80 until use. Aliquots of inhibitors were stored at -80 
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2.2 Methods 
2.2.1 HMC-1 Cell Cultures 
HMC-1 cells were maintained in IMDM at a density between 3 and 7 x 10^  
cells/ml supplemented with 10 % (vol/vol) HI-FCS, and 1.2 mM a-thioglycerol 
(Sigma-Aldrich Co). They were kept under a humidified atmosphere with 5 % 
CO2 at 37 °C and subcultured every 4 days. In studying the signaling 
mechanisms, HMC-1 cells were first treated with or without signaling molecule 
inhibitor for 35 min to block specific signaling pathway. The cells were then 
stimulated with different TLR ligands for desirable time before harvest. 
2.2.2 Purification of Buffy Coat Eosinophils by MACS and Eosinophil 
Culture 
CD 16 is expressed on all leukocytes except eosinophils. Fresh human buffy 
coat obtained from the Hong Kong Red Cross Blood Transfusion Service was 
diluted 1:2 with PBS (IX) and centrifuged using an isotonic Percoll solution 
(Amersham Biosciences, density 1.082 g/ml) at 4 for 30 min at 1,000 g in a 
50 ml centrifuge tube. The eosinophil-rich granulocyte fraction was collected 
and washed twice with PBS containing 2 % HI-FCS. The mononuclear cells at 
the interface were removed. Then the eosinophils-rich granulocytes layers were 
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then incubated with anti-CD 16 magnetic beads (Miltenyi Biotec Inc) at 4 ^C for 
45 min and CD16-positive neutrophils were depleted by passing through a LS 
column (Miltenyi Biotec Inc) within a strong magnetic field. In this preparation, 
the drop-through fraction contained eosinophils with a purity of at least 99 % 
were assessed by double staining of eosin and hematoxylin. The viability of 
eosinophils was at least 98 % as assessed by trypan blue exclusion assay. The 
isolated eosinophils were cultured in RPMI 1640 medium, supplemented with 
10 % HI-FCS. In studying the signaling mechanisms, eosinophils were first 
treated with or without signal transduction inhibitors for 35 min. To determine 
whether cytokine release involved protein production, mRNA transcriptional 
inhibitor actinomycin D and translational inhibitor cycloheximide were prior 
incubated with eosinophils for 35 min. The cells were then stimulated with 
chymase for desirable time before harvest. 
2.2.3 Total Cellular RNA Extraction 
Total RNA from HMC-1 cells (3 x 10^  cells) was extracted using RNeasy 
Mini Kit (Qiagen GmbH). Briefly, HMC-1 cells were lysed and homogenized in 
the presence of a highly denaturing guanidinium isothiocyanate-containing 
buffer that immediately inactivated RNases to ensure isolation of intact RNA. 
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Ethanol was added to provide appropriate binding conditions and the samples 
were then applied to an RNeasy mini spin column where the total RNA bound to 
the membrane and contaminants were efficiently washed away. High-quality 
RNA was then eluted in 30 |LI1 of RNase-free water after 15 min on-column DNA 
digestion. 
2.2.4 RT-PCR 
Extracted total RNA was reversely transcribed into first-strand cDNA using 
First-Strand cDNA Synthesis Kit (Amersham Biosciences) according to 
instruction of manufacturer. PGR was performed in a reaction mixture containing 
3 mM MgCh, 200 |LIM dNTPs, 1 unit of AmpliTaq Gold DNA polymerase 
(Perkin Elmer Corp), 50 pmol of 5' and 3’ primers (Invitrogen Corp) in PGR 
reaction (30 sec at 94 for denaturing, 30 sec at annealing temperature specific 
for each pair of primers and 45 sec at 72 for elongation) for 25 to 35 cycles 
for different primers, after an initial 12 min of denaturation at 94 ""C. All RT-PCR 
were performed in the linear range of the PGR reaction according to the 
preliminary experiment. After the amplification reaction using PTC-200 DNA 
Engine™ (Bio-Rad Laboratories Inc), PGR products were electrophoresed on 
2 % agarose gel in IX TAE buffer (pH 8.0) and stained with ethidium bromide. 
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2.2.5 Agarose Gel Electrophoresis 
Agarose gels (2 % w/v) were prepared in IX Tris-acetate buffer (TAE) (pH 
8.3) containing 0.5 |Lig/ml ethidium bromide. PGR product (5 jLil) [mixed with 2 
|il of fast dye loading buffer (5X) containing 0.05 % (w/v) bromophenol blue, 40 
% (w/v) sucrose, 0.1 M EDTA (pH 8.0) and 0.5 % SDS] or DNA ladder marker 
was loaded into the sample wells of agarose gel which was immersed in IX TAE. 
Electrophoresis was performed in a horizontal electrophoretic tank under 
constant voltage of 180 V for 20 min. The bands were visualized under UV. 
Images were taken from Gene Genius Gel Documentation System (Syngene Inc, 
Cambridge, UK). 
2.2.6 Flow Cytometry Analysis 
2.2.6.1 Immunophenotyping of Cells by Flow Cytometry 
HMC-1 cells (5 x 10^  cells) or human eosinophils (5 x 10^  cells) after 
preceding treatment were resuspended with cold PBS supplemented with 0.5 % 
HI-FCS. After blocking with 2 % human pooled serum for 20 min at 4 and 
washed with PBS supplemented with 0.5 % HI-BSA, cells were incubated either 
with FITC-conjugated mouse anti-human ICAM-1, ICAM-3, CD18 or CD62L 
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monoclonal (mAb) antibody or FITC-conjugated mouse IgG] isotype for 30 min 
at 4 in darkness. After washing, cells were finally resuspended in 1 % 
paraformaldehyde for fixation. Cell surface expression of ICAM-1, ICAM-3, 
CD 18 and CD62L was then analyzed by flow cytometry (FACSCalibur™, BD 
Biosciences) in terms of mean fluorescence intensity (MFI). 
2.2.6.2 Annexin V-FITC/PI Apoptosis Detection 
TAGS™ annexin V-FITC/PI staining kit (Trevigen Inc) was used to quantify 
the percentage of cells undergoing apoptosis. It relied on the property of cells to 
lose membrane asymmetry in the early phases of apoptosis in which, the 
membrane phospholipids phosphatidylserine was translocated from the inner 
leaflet to the outer leaflet of the plasma membrane. Annexin V Incubation 
Reagent (100 |LI1 per 10^  cells) was prepared by combining 100 |LI1 of PBS, 5 |ul of 
PI, 10 |il of annexin V-FITC conjugate. Treated and unstimulated eosinophils (5 
X 10^ cells) were harvested and washed with cold PBS. The cells were then 
resuspended in 100 |LI1 of the Annexin V Incubation Reagent, and incubated in 
darkness at room temperature. After 15 min, 400 )LI1 of cold PBS was added per 
100 |Lil of each reaction and the samples were analyzed immediately by flow 
cytometer (FACSCalibur™, BD Biosciences). 
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2.2.6.3 Quantitative Analysis of IL-6, CXCL8 and CCL2 
IL-6, CXCL8 and CCL2 concentrations in culture supernatant were 
measured by CBA Flex Sets (BD Biosciences) using FACSCalibur™ flow 
cytometer. The bead populations could be resolved in the FL3 and FL4 channel 
of flow cytometer. First, 50 [ l\ culture supernatants were incubated with 50 fil 
capture beads mixtures and 50 fil phycoerythrin (PE)-conjugated detection 
antibodies. The mixture formed a sandwich complex and after 3 h incubation, the 
capture beads were washed and re-suspended for sample data acquisition using 
Cell Quest. The sample results were finally generated in graphical format using 
FCAP Array™ (BD Bioscience) analysis software. 
2.2.7 Protein Array Analysis of Cytokines Release 
HMC-1 cells (2 x 10^  cells) or eosinophils (2 x 10^  cells) were treated and 
culture supernatants were collected after 24 h incubation at 37 The 
expression profiles of 79 different cytokines were assessed semiquantitatively 
using antibody-based RayBio human cytokine array V (RayBiotect Inc, Norcross, 
GA, USA). The cytokine map of array was listed in Appendix. 
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2.2.8 Quantitative Analysis of CXCLl 
Culture supernatant were collected after treating the eosinophils (5 x 10^  cells) 
for 8 h, 24 h or 48 h. Concentration of CXCLl was measured by ELISA with a 
detection limit of 10 pg/ml (R&D Systems Inc). 
2.2.9 Total Protein Extraction 
Eosinophils (8 x 106 cells) or HMC-1 cells (3 x 10^  cells) were washed twice 
with PBS and lysed in 150 \i\ cell lysis buffer (BD Biosciences). Total proteins 
were aliquoted in 50 )LI1 and stored at -20 until use. Protein concentrations 
were determined using Bradford reagent (Bio-Rad Laboratory Inc). 
2.2.10 SDS-PAGE 
A Bio-Rad Mini-PROTEAN apparatus was used for discontinuous 
polyacrylamide gel electrophoresis. The recipe of the upper stacking gel was 
0.187 M Tris-HCl, pH 6.8, 5 % aery lam ide, 0.1 % SDS, 0.1 % APS, 0.1 % 
TEMED, while the lower separating gel was 0.375 M Tris-HCl, pH 8.8, 12.5 % 
acrylamide, 0.1 % SDS, 0.1 % APS, 0.075 % TEMED. The lower separating gel 
solution mixed as the above recipe was casted into the vertical gel glass plates of 
sizes [Inner: 7.3 x 10.2 x 0.1 cm; Outer: 8.3 x 10.2 x 0.1 cm (H x W x D)]. A 
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layer of 0.1 % SDS was laid on the top to assist the formation of a straight line 
interphase. After the separating gel was set, the 5 % polyacrylamide stacking gel 
was set with a comb to form ten wells of sizes 1.5 x 0.5 x 0.1 cm (H x W x D). 
Electrophoresis was carried out using Tris-Glycine-SDS Running Buffer at a 
constant voltage of 100 V for about 100 min. After electrophoresis, the gel was 
either used for immiinoblotting or stained with Coomassie blue brilliant dye 
(0.2 % R250 Coomassie brilliant blue, 50 % methanol, 10 % acetic acid) for 1 h 
and de-stained with a solution of 5 % methanol and 10 % acetic acid. 
2.2.11 Western Blotting Analysis 
Equal amount of proteins (15 )Lig) were subjected to 10 % SDS 
electrophoresis separated proteins and blotted onto a PVDF membrane 
(Amersham Biosciences). The membrane was then blocked with 3 % skim milk 
in TEST for 1 h. Primary antibodies against human TLRl-9 or signaling 
molecules (total or phosphorylated ERK, p38 MAPK, JAK2, Akt and IKB) were 
used to probe the specific protein on the membranes at 4 overnight. After 
washing, membranes were incubated with a secondary antibody, either goat 
anti-rabbit or goat anti-mouse IgG which was conjugated with horseradish 
peroxide (Amersham Biosciences) for 1 h at room temperature. After washing, 
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the antibody-antigen complexes were detected by ECL detection kit according to 
the manufacturer's instructions (Amersham Biosciences). 
2.2.12 Chemotactic Migration Analysis 
Eosinophils (1 x 10^  cells) were treated with chymase at different 
concentrations for 16 h. With 25 )LI1 RPMI medium without cells but containing 
various concentrations of chymase were added into the lower wells of Boyden 
chamber, 50 |LI1 of chymase-treated eosinophils were added to the upper wells. 
PCTE membranes were used to separate the upper and lower wells. After 6 h 
incubation at 37 °C, cell numbers of each lower well were counted. Al l 
treatments were done in triplicate and cells numbers were taken as the mean cell 
number within three microscopic views in high magnification power (400x). 
2.2.13 Statistical analysis 
Data in figures were presented either as histograms plus SD or as mean ± SD 
in curves. Differences between groups were assessed by the unpaired student 
t-test. A probability p < 0.05 was considered significantly different. Al l analyses 
were performed using the Statistical software GraphPad Prism (GraphPad 
Software, Inc, San Diego, CA, USA). 
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Chapter 3 
Effects of Mast Cell Derived Chymase on Human 
Eosinophils and the Signaling Mechanisms: 
Implication in Allergic Inflammation 
3.1 Introduction 
Allergic inflammation is characterized by accumulation of tissue resident 
mast cells followed by the influx and persistence of the eosinophils in relevant 
tissues. Activated mast cells release mediators that contribute to eosinophil 
activation, followed by the cascade of the recruitment and stimulation of other 
immune effector cells. Apart from the well-studied histamine, unique proteases 
chymase and tryptase, which exclusively produced in mast cell secretory 
granules provided another communication pathway for mast cells and 
eosinophils (Ezeamuzie & Philips, 2000). 
Previous studies have demonstrated that chymase exhibits potant 
proinflammatory effects: introduction of chymase into skin or peritoneum of 
animal models yielded increased microvascular permeability and marked 
accumulation of inflammatory cells [including eosinophils, monocytes, 
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neutrophils and macrophages (Terakawa, 2006; Tani et al., 2000; He et al., 
1998)]. Although the chymase-induced increase of microvascular permeability 
has lower amplitude than histamine, it is of greater longevity (He et al, 1998). 
Chymase is also known to exhibit a number o f properties that are consistent with 
its role in tissue remodeling and inflammation (Table 3.1). 
The mast cell subtype MCTC is predominant in skin and peritoneal but not in 
lungs (Pmssin & Metcalfe，2003)，so it is reasonable to speculate that chymase is 
a critical factor in eliciting and perpetuating dermal inflammatory diseases such 
as AD. Candidate gene studies showed that chymase encoding gene (CMA) could 
be a susceptible gene that is related to AD development (Morar et al., 2006). 
Besides, increased chymase containing mast cells have been identified in skin 
biopsies of AD patients (Badertscher et al., 2005). The use of chymase inhibitors 
SUN13350 and SUN C8257 was also effective in reducing AD symptoms 
(Watanabe et al., 2002; Tomimori et al., 2002). 
In this study, we would like to investigate how chymase acts as a stimulant 
for human peripheral eosinophils. By treating isolated eosinophils with human 
skin-derived chymase, we determined the effect of chymase on cell viability, 
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migration properties, release o f cytokines and chemokines. Finally, the 
underlying signaling mechanisms were also of our interest. Phosphorylation 
states o f selected signaling molecules were detected by Western blot analysis and 
the effect of six specific signaling inhibitors were used to elucidate the possible 
pathways responsible for each chymase-induced effect. 
63 
Chapter 3 Chymase on Eosinophils 
II • I I I • 11 I 
Chymotrypsin-like serine endopeptidase 
Type of protease (皿 4 . 2 1 . 3 9 ) 
30kDa 
Molecular size . .,、 
(274 amino acid) 
Neutral: pH 7-9 
Optimal pH 
(store in acidic mast cell granule pH 5.5) 
1. Activate cytokine precursor o f l L - i p , SCF and TGF-P 
. , . , . . . 2. Activate metalloproteases to release fibronectin 
Biological activities 
3. Activate interstitial procollagenase and release 
membrane-bound TGF-P from extracellular matrix 
Table 3.1 Essential information about chymase. (Takai et al., 2004; Wu et al., 
2004; Welle, 1997; Taipale etal., 1995; Saarinen etaL, 1994) 
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3.2 Results 
3.2.1 Effects of Chymase on Eosinophil Survival 
Figure 3 .1 shows that the viability o f eosinophils was significantly increased 
when treated with chymase. After 24 h o f incubation with chymase (0.2-1 pig/ml)， 
the percentage of viable eosinophils increased from 56 % to 65 % in a 
dose-dependent manner. Positive control [IL-3 (20 ng/ml), IL-5 (20 ng/ml) and 
GM-CSF (50 ng/ml)] and negative control [BAY l 17083 (10 nM) ] were used for 
setting up the four quadrants. 
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Figure 3.1 Effects of chymase on the viability of eosinophils. Eosinophils (5 x 
10^ cells) were untreated or treated with chymase (0.2-1 |ig/ml) for 24 h. 
Viability of eosinophils was determined by flow cytometry. The population of 
viable cells was characterized by low mean MFI of both annexin-V-FITC and 
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PI-PE (in the lower left quadrant). (A) Percentages of viable cells were 
determined by triplicate experiments. * p < 0.05, * * p < 0.01. Representative 
dot-plot of (B) medium control and (C) chymase-treated (1 lag/ml) eosinophils 
are shown. 
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3.2.2 Effects of Chymase on the Adhesion Molecule Expression of 
Eosinophils 
Figure 3.2 shows that chymase (1 pig/ml) could upregulate surface expression 
of CD18 but not CD62L, ICAM-1 and ICAM-3. Figure 3.3 shows the kinetics 
and dose response o f chymase-inducing effects on the surface expression o f 
CD18. Chymase (0.2-1 iig/ml) could significantly upregulate CD18 expression. 
Maximal expression of CD 18 was detected at 0.5 |_ig/ml for 24 h. 
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Figure 3.2 Effects of chymase on the surface expression of CD 18, CD62L, 
ICAM-1 and ICAM-3. Eosinophils (5 x 10^ cells) were treated with or without 
chymase (1 )ig/ml) for 24 h. Surface expression of (A) CD 18, (B) ICAM-1 (C) 
ICAM-3 and (D) CD62L on eosinophils were determined by flow cytometry. 
Medium control was shown in black lines while chymase-treated cells were 
shown in green lines. Red lines are the isotypic control. Results are expressed as 
histograms of relative cell counts with fluorescence intensity. These figures are 
representatives from three independent experiments with similar results. 
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Figure 3.3 Effects o f chymase on the expression o f CD 18. Eosinophils (5 x 10^ 
cells) were cultured w i th or without chymase (0.2-1 lag/ml) for 8, 16 and 24 h. 
Surface expression o f adhesion molecules o f 10, 000 cells was analyzed by flow 
cytometry as M F I . Results have been normalized by subtracting appropriate 
isotypic control and are expressed as the arithmetic mean 士 SD of three 
independent experiments. * / ? < 0.05 when compared with medium control. 
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3.2.3 Effects of Chymase on the Chemokinetic Properties on Eosinophils 
To verify that chymase could enhance the chemokinetic behavior of 
eosinophils, checkerboard analysis was performed to show whether chymase 
treatment (0.01-1 pig/ml) could increase the migration of eosinophils to the lower 
wells o f Boyden chamber. As shown in Table 3.2, eosinophils treated with 
chymase (0.1 lag/ml and 1 |ig/ml) could facilitate the migratory behavior of 
eosinophils. As the increases of cell number were correlated to the chymase 
concentration on the upper compartment but not the lower compartment, thereby 
it was indicated that chymase could exert a chemokinetic effect rather than 
chemotactic to eosinophils. 
71 
Chapter 3 Chymase on Eosinophils 
Upper Compartment (}ig/ml) 
0 ^ 1 
Lower Compartment (|ig/ml) 
0 16.6 ± 7.4 20.4 ± 8.5 22.3 ± 15.7 31.1 ± 7.7 * * 
0.01 21.2 土 6 . 2 2 0 . 7 土 6.8 3 0 . 3 土 9 . 8 26.6 土 1 2 . 6 
0 . 1 21.2 土 7.1 2 3 . 4 土 1 2 . 9 29.7 土 11.1 33.4 土 9 . 2 
1 1 8 . 1 土 8 . 4 2 2 . 1 土 5.3 2 8 . 1 土 9 . 4 * * 3 4 . 4 土 5.8 * * * 
Table 3.2 Chemokinetic effect o f chymase on eosinophils. Eosinophils (1 x 10^ 
cells) were treated with chymase (0.01-1 pig/ml) for 16 h. They were then added 
into upper wells o f a Boyden chamber while the RPMI medium with chymase 
(0.01-1 |Lig/ml) but no cells were added into lower wells. Migration was carried 
out for 6 h and the numbers o f cells migrated to the lower wells were counted. 
The experiments were repeated for five times and the mean 土 SD were shown. 
* * < 0.01, * * * p < 0.001 when compared with the medium control of the upper 
compartment. 
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3.2.4 Effects of Chymase on the Release of Chemokines and IL-6 from 
Eosinophils 
Figure 3.4 illustrates the cytokine expression profiles o f chymase-treated (1 
j ig/ml) eosinophils using antibody based human cytokine protein membrane 
array, which acted as a screening test. Chymase could activate eosinophils to 
markedly induce the release of chemokines CXCL l , CXCL8, CCL2 and 
inflammatory cytokine IL-6 among the 79 different cytokines being screened 
after 48 h incubation when compared wi th that of medium control. The cytokine 
list with symbol and position information is given in appendix. Figure 3.5 shows 
that the release of the IL-6, CCL2 and CXCL8 were concentration- and 
time-dependent while C X C L l was only concentration-dependent. Maximal 
increase of chemokines was detected after 48 h of incubation while IL-6 was the 
highest at 24 h. 
Figure 3.6 shows the effect of actinomycin D (0.1 piM) and cycloheximide 
(10 | iM) on chemokines and IL-6 release by eosinophils after 24 h incubation. 
The transcriptional inhibitors could totally abolish the release of CCLl , CXCL l 
and CXCL8 while only reduced half of the IL-6 secretion. This may because 
some of released IL-6 was preformed in eosinophils before chymase activation. 
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Figure 3.4 Representative profile of the release of cytokines from 
chymase-treated eosinophils. Eosinophils (2 x 10^ cells) were treated with or 
without chymase (1 |Lig/ml) for 48 h. Cell-free supernatant was then harvested 
and 79 different cytokines in the supernatant were semiquantitated using 
antibody-based Ray Bio human cytokine array V. Positive and negative controls 
were designated at (la, lb, Ic, Id, 8j, 8k) and (le. If, 8i) respectively. Triplicate 
experiments were performed with essentially identical results. 
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Figure 3.5 Chymase-induced releases of (A) CXCL l (B) CXCL8, (C) CCL2 and 
(D) IL-6 from eosinophils. Eosinophils (5 x 10^ cells) were cultured with or 
without chymase (0.2-1 |ig/ml) for 16, 24 and 48 h. Eosinophils release of 
chemokines and IL-6 into the culture supernatant were determined by CBA 
FlexSet kit using flow cytometry and ELISA. Results are expressed as the mean 
土 SD were shown. * p< 0.05，** p < 0.01, * * * p < 0.001 when compared with 
the medium control. 
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Figure 3.6 Effect of actinomycin D and cycloheximide on chymase-induced 
release of (A) CXCLl，(B) CXCL8，(C) CCL2 and (D) IL-6. Eosinophils (5 x 
10^ cells) with or without chymase treatment (1 |ig/ml) were pre-incubated with 
actinomycin D or cycloheximide for 35 min. Chemokines or IL-6 released into 
the supernatant were quantified by CBA FlexSet kit using flow cytometry and 
ELISA. Results are expressed as the mean 土 SD were shown. * / ? < 0.05, * * / ? < 
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0.01, * * * p < 0.001 when compared with the chymase-treated control. 
ActD: Actinomycin D (0.1 | iM) 
Cyclo: Cycloheximide (10 piM) 
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3.2.5 Signal Transduction Mechanism Involved in Regulating 
Chymase-induced Effects on Eosinophils 
3.2.5.1 Effects o f Signal Pathway Inhibitors on Chymase-induced Release of 
Chemokines and IL-6 
In Figure 3.7, it shows that only p38 M A P K pathway inhibitor SB203580 
and N F - K B pathway inhibitor B A Y l 17082 could significantly reduce the 
chymase-induced secretion of CXCL l . For IL-6, p38 M A P K pathway inhibitor 
SB203580, N F - K B pathway inhibitor B A Y l 17082 and ERK pathway inhibitor 
PD98059 could block the chymase-induced IL-6 secretion. For CXCL8 and 
CCL2, except I N K pathway inhibitor SP600125, pre-treatment of the rest of five 
inhibitors could significantly reduce the chymase-induced secretion. 
3.2.5.2 Effects of Inhibitors on Chymase-induced Upregulation of Cell Sruface 
Expression of CD 18 
As shown in Figure 3.8，pre-treatment of eosinophils (5 x 10^ cells) with p38 
MAPK pathway inhibitor SB203580, ERK pathway inhibitor PD98059, PI3K 
pathway inhibitor LY294002 and N P - K B pathway inhibitor B A Y l 17082 for 35 
min could significantly suppress the chymase-induced upregulation of CD 18. 
JAK pathway inhibitor AG490 and JNK pathway inhibitor SP600125 did not 
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exhibit any effect on the chymase-induced cell surface CD 18 upregulation. 
3.2.5.3 Phsophorylation o f p38 MAPK, ERK, JAK, Akt and IKB in 
Chymase-treated Eosinophils 
Figure 3.9 presents the time courses o f phosphorylation o f five signaling 
molecules. Chymase (1 |ig/inl) could rapidly induce phosphorylation o f p38 
M A P K and Akt at 5 min. While for ERK, JAK2 and IKB, phosphorylation were 
taken place after 15 min o f chymase challenges and sustained to 30 min. 
Table 3.3 is the summary of the results of 3.2.5. It shows the effects of each 
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Figure 3.7 Effects o f AG490, SB203580, PD98059，LY294002, SP600125 and 
B A Y l 17082 on the chymase-induced (A) CXCL l , (B) CXCL8，(C) CCL2 and 
(D) IL-6 secretion in eosinophils. Eosinophils (5 x 10^ cells) were pretreated with 
inhibitors for 35 min, followed by incubation with or without chymase (1 ng/ml) 
in the presence of inhibitors for further 24 h. Release of chemokines and IL-6 in 
the culture supernatant were determined by CBA FlexSet by f low cytometer and 
ELISA. Results are expressed as the mean 土 SD from three independent 
experiments. DMSO (0.1 %) was used as the DMSO control. *p < 0.05, ** /? < 
0.01, * * * / ? < 0.001 when compared with the chymase control. 
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AG: AG 490 (3 [ iM) 
SB: SB203580 (7.5 \ iM) 
PD: PD98059(10 _ 
LY : L Y 294002 (5 | iM) 
SP: SP600125 (3 _ 
BAY: B A Y l 17082(1 _ 
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Figure 3.8 Effects o f AG490，SB203580, PD98059, LY294002, SP600125 and 
B A Y l 17082 on the chymase-induced upregulation of CD 18 on eosinophils. 
Eosinophils (5 x 10^cells) were pretreated with inhibitors for 35 min, followed 
by incubation with or without chymase (1 jiig/ml) in the presence o f inhibitors for 
further 24 h. The expression of CD 18 was measured by f low cytometer and 
expressed as MFI. Results are expressed as the mean 土 SD from three 
independent experiments. DMSO (0.1 %) was used as the DMSO control. < 
0.01, * * * p < 0.001 when compared with the chymase control. 
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PD: PD98059 (10 ^iM) 
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Figure 3.9 Effects o f chymase on activation of (A) p38 MAPK, (B) ERK, (C) 
JAK2, (D) Akt and (E) IKB. Eosinophils (8 x 10^ cells) were treated with or 
without chymase (1 jig/ml) for the period of time indicated. Total cellular 
proteins were extracted for the detection of total and phosphorylated signaling 
proteins by Western blot analysis. Experiments were performed in three 
independent experiments with essentially identical results, and representative 
blots are shown. 
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I Inhibitors 
Chymase-induced (Target signaling pathway) 
effects AG490 SB203580 PD98059 LY294002 SP600125 BAY117082 
(JAK) (p38 MAPK) (ERK) (Akt) (JNK) (NF-KB) 
CD18 n.s. * * * n.s. * 
CCL2 * * * * as. * 
CXCLl n.s. * n.s. n.s. n.s. * 
CXCL8 * * * * n.s. * 
IL-6 n.s. * * n.s. n.s. * 
Table 3.3 Summary o f the effects of inhibitors on chymase-induced upregulation 
of CD 18 and release of chemokines and IL-6. * Significant inhibition of 
chymase-induced effect (all p < 0.05); n.s. no significant inhibition detected (all 
p > 0.05) 
87 
Chapter 3 Chymase on Eosinophils 
3.3 Discussion 
With the colocalization of mast cells and eosinophils at the inflamed site such 
as skin lesion o f AD, it is reasonable to suggest that the two leukocytes interact 
and act on each other during inflammation. In this study, results showed that 
chymase could significantly increase the viability of eosinophils to prolong 
eosinophilia at inflamed sites. Surface expression of adhesion molecule CD 18 on 
eosinophils was also upregulated for its transmigration into inflammatory sites 
(Saban et al., 1997). Moreover, checkerboard analysis revealed that chymase 
(0.5-1 |ag/ml) could promote chemokinesis of eosinophils in a dose-dependent 
manner, which is similar to the chymase action on lymphocytes (Tani et al., 
2000). 
The releases of chemokines and inflammatory cytokines have been shown to 
play important pathologic roles in allergic inflammation, for example, in AD 
(Homey et al,, 2006). Chymase could activate eosinophils to release chemokines 
CCL2, CXCL l , CXCL8, and pro-inflammatory cytokine IL-6, which were 
commonly released by eosinophils activated by allergen house duct mite protein 
Der P I and Th2 cytokine IL-25 (Wong et al., 2005; Wong et al., 2006). The CXC 
Chemokines CXCL l and CXCL8 are important for neutrophil and T-lymphocyte 
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specific accumulation in inflamed skin (Schroder, 1995). The CC Chemokine 
CCL2 could recruit both monocytes and eosinophils (Dunzendorfer et al., 2001). 
As chymase could increase the microvascular permeability (He et al., 1998), 
increased secretion of these mediators could further enhance eosinophilia and 
accumulation of various leukocytes to orchestrate the inflammation. 
AD progression is a biphasic reaction. Th2 response dominated in the early 
acute phase while Th l effects were responsible for the late chronic development 
of AD symptoms (Chen et al., 2004). IL-6, the proinflammatory cytokine was 
largely increased in chymase-stimulated eosinophils (over 100-fold) and its 
concentration was correlated to AD disease severity (Bunikowski et al., 2001). In 
dermal inflammation, eosinophils might collaborate with T lymphocytes, 
endothelial cells and keratinocytes to upregulate local and circulating IL-6 
concentration (Neuber et al.’ 1995; Toshitani et al” 1993). Chymase might 
resemble the Th2 cytokine IL-17 and IL-25 by increasing CXCL l and CXCL8 
production so as to exaggerate Th2 inflammation during the early phase of 
inflammation (Witowski et al, 2000; Wong et al, 2006). 
Besides, serum CXCL8 concentrations were positively correlated with the 
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severity o f A D because activated peripheral blood mononuclear cell could 
increase CXCL8 secretion (Kimata et al； 1994; Yousefi et al., 1995). According 
to our study, eosinophils, the circulating granulocytes under chymase stimulation 
may also make some contribution on serum CXCL8 elevation. 
Comparing chymase to another mast cell protease tryptase, their roles in 
allergic inflammation were similar. Tryptase could induce the production of 
CCL2, CXCL8 and IL-6 from human endothelial cells and eosinophils, enhance 
the chemotactic properties of mast cells and induce neutrophil infiltration 
(Temkin et al., 2002; Kinoshita et al., 2005; Compton et al, 2000). Moreover, 
tryptase has been well studied for the pathological roles in allergic disease 
particularly in allergic asthma (Cairns, 2005; Reed & Kita, 2004; Rice et al, 
1998). 
Cytokine and chemokine-mediated signal transductions in eosinophils, 
including the MAPK pathway, JAK-STAT pathway, PI3K pathway and N F - K B 
pathway, have been intensively investigated over the past decade (Wong et al., 
2004; Wong et a!., 2002). In this study, we have found that chymase could 
induce the phosphorylation of p38 MAPK and Akt after 5 min while 
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phosphorylated ERK, JAK2 and IKB were detected after 15 min of chymase 
activation. Besides, results showed that CD 18 expression, chemokines and IL-6 
secretion were regulated by different intra-signaling pathways. 
Recent reports have shown that p38 MAPK and ERK but not JNK were 
involved in chymase-induced chemotaxis and degranulation in eosinophils 
(Terakawa et al, 2005; Terakawa et al., 2006). It is consistent with our results 
that activation o f JNK phosphorylation was not detected (data not shown) and 
JNK selective inhibitor SP600125 could not inhibit the chymase-mediated 
effects. Although the involvement o f PI3K, N F - K B and JAK pathway has not 
been reported in chymase action, the P I 3 K and N F - K B pathways were involved 
in tryptase activation on endothelial cells to increase CXCL8 (Ma et al.’ 2006). 
Further investigation of other signaling pathways could employ flow cytometry 
staining, ELISA of phosphorylated protein and small interfering RNA. 
In summary, this part of study investigated how chymase, one of the mast 
cell specific mediator, in modulating the function of eosinophils. Our results 
provided additional information and clues on the pathological role of mast cells 
in allergic inflammation such as AD. 
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Chapter 4 
TLR-mediated Effects and Signal Transduction 
Mechanism of HMC-1 Cells 
4.1 Introduction 
In 1997, a mammalian family of proteins with homology with the Drosophila 
Toll protein was identified and named as TLR. They are involved in the bridging 
of innate and adaptive immune system by recognizing pathogen-associated 
molecular patterns which are produced by viruses, bacteria, and fungi (Table 4.1). 
To date, ten TLR have been identified in humans (Chaudhuri et al., 2005). 
Apart from pathogen recognition and induction of innate immunity, recent 
advance also showed that TLR are associated with atopic diseases such as 
allergic asthma by increasing airway responsiveness (Homer, 2006). In allergic 
asthma and rhinitis patients, mast cell infiltration was demonstrated by increased 
mast cell number in nasal mucosal, bronchial mucosal and sputum biopsy 
(KleinJan et al., 2000; Macfarlane et al., 2000; Gauvreau et al., 2000). 
Infiltrations of leukocytes are highly regulated by expression of various adhesion 
molecules as mentioned in Chapter 1. 
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In the present study, we investigated the role o f TLR in mediating allergic 
inflammation by studying their effects on adhesion molecule expressions of 
human mast cells. After evaluating the TLR expression profile o f a human mast 
cell line HMC-1 cells, the effect of TLR ligands on the expressions of adhesion 
molecules were measured by f low cytometry. Besides, the involvement o f ERK 
pathway, a crucial signaling pathway in regulating adhesion molecules 
expression and TLR signaling was investigated by using selective ERK pathway 
inhibitor and Western blot analysis. 
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TLR Family Member TLR Ligands 
T L R l Lipopeptides, Myobacterial lipoprotein 
TLR2 Peptidoglycan, Zymosan 
TLR3 Poly (I:C) (Viral dsDNA) 
TLR4 Lipopolysaccharide, Heat shock protein 60’ Fibrinogen 
TLR5 Flagellin 
TLR6 Peptidoglycan, Zymosan 
TLR7 ssRNA (virus), Imiquimoid, Resiquimoid 
TLR8 Resiquimoid 
TLR9 CpG oligonucleotides 
TLRIO Unknown 
Table 4.1 Human TLR family members and their selected ligands. (Modified 
from Marshall et al” 2003 & Feleszko et al., 2006) 
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4.2 Results 
4.2.1 Expression of Adhesion Molecules on HMC-1 cells 
To study the effect o f TLR ligands on the expressions of adhesion molecules, 
basal expressions of four representative adhesion molecules which belong to 
three different families were examined on HMC-1 cells. As shown in Figure 4.1, 
HMC-1 cells constitutively expressed ICAM-1 and ICAM-3 but not CD18 
(integrin) and CD62L (selectin) in resting state. 
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Figure 4.1 Expression of four adhesion molecules on resting HMC-1 cells. 
HMC-1 cells (5 x 10^ cells) stained with mAb of IgGi isotypic control (red line) 
and (A) ICAM-1, (B) ICAM-3, (C) CD18 and (D) CD62L (black line) were 
determined by flow cytometry. Data are presented as histograms of relative cell 
counts with fluorescence intensity. These are representative figures from five 
independent experiments with similar results. 
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4.2.2 TLR Expression Profile on HMC-1 cells 
To evaluate the expression profile of TLR on HMC-1 cells. Figure 4.2 
demonstrates the protein expression o f TLRl -9 on HMC-1 cells. HMC-1 cells 
could mildly express T L R l , TLR2, TLR4, TLR5 and TLR6 while TLR7 and 
TLR9 have a relative strong expression. TLR3 and TLR8 were not expressed on 
HMC-1 cells. 
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Marker TLR 1 TLR 2 TLR 3 TLR 4 TLR 5 
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Figure 4.2 Protein expressions of TLRl -9 on HMC-1 cells. Total cellular 
proteins from HMC-1 cells were extracted and equal protein extracts (15 pig) 
were used for the detection of TLRl -9 by Western blot analysis. Experiments 
were performed in triplicate with essentially identical results. 
MW: Molecular weight 
kDa: Kilodaltons 
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4.2.3 Effects of TLR Ligands on HMC-1 Cell Adhesion Molecule 
Expressions 
Figure 4.3 shows the effect o f TLR ligands on the expressions of ICAM-1 
and ICAM-3 on HMC-1 cells. TLR2 ligand peptidoglycan and zymosan, TLR5 
ligand flagellin, TLR7 ligand R837 (Imiquimoid) and TLR9 ligand CpG D N A 
were used to stimulate the HMC-1 cells for 24 h. Among the ligands, only TLR7 
ligand R837 could upregulate the expression o f both ICAM-1 and ICAM-3. 
TLR2 could form functional homodimers and heterdimers wi th either T L R l or 
TLR6. 
Figure 4.4 shows the dose-dependent effects of ICAM-1 and ICAM-3 
expression by TLR7 ligand as both of them were increased gradually from 
5-20 |ag/ml. It was also a time-dependent effect as the maximal responses 
occurred after 48 h incubation with TLR7 ligand for both ICAM-1 and ICAM-3. 
At gene level, TLR7 ligand could upregulate the gene expression of ICAM-1 
and ICAM-3 after 24 h and 48 h incubation respectively as shown in Figure 4.5. 
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Chapter 4 TLR on HMC-1 cells 
Figure 4.3 Effects o f TLR ligands on surface expression of ICAM-1 and ICAM-3. 
HMC-1 cells (5 x 10^ cells) were treated with or without (A) TLR2 ligand 
peptidoglycan, (B) TLR2 ligand zymosan, (C) TLR5 ligand flagellin, (D) TLR7 
ligand R837 and (E) TLR9 ligand CpG for 24 h. Surface expression o f ICAM-1 
and ICAM-3 on HMC-1 cells were determined by flow cytometry. Controls are 
shown in solid lines while TLR-ligand treated cells are shown in dotted lines. 
Results are expressed as histograms o f relative cell counts with FL l -F ITC MFI. 
These figures are representatives from three independent experiments with 
similar results. 
IC: Isotypic control 
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Figure 4.4 Effects of TLR7 ligand on the expression of (A) ICAM-1 and (B) 
ICAM-3. HMC-1 cells (5 x 10^ cells) were cultured with or without TLR7 ligand 
(5-20 |ig/ml) for 8, 24 and 48 h. Surface expression of adhesion molecules of 
10, 000 cells was analyzed by flow cytometry as MFI. Results have been 
normalized by subtracting appropriate isotypic control and are expressed as the 
arithmetic mean 士 SD of three independent experiments. < 0.05, < 0.01 
when compared with medium control. 
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Figure 4.5 Effects o f TLR7 ligand on gene expression of ICAM-1 and ICAM-3 
on HMC-1 cells. The mRNA expression of P-actin, ICAM-1 and ICAM-3 of 
HMC-1 cells (3 x 10^ cells) after TLR7 ligand (20 lag/ml) treatment for (A) 12 h 
or (B) 24 h were analyzed by RT-PCR. Representative results are shown from 
triplicate experiments with essentially identical results. 
C: Medium control 
R: R837 treated HMC-1 cells 
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4.2.4 TLR7-induced Phosphorylation of ERK and Effect of PD98059 on 
TLR7-induced ERK Phosphorylation 
Figure 4.6 demonstrates that TLR7 ligand increased the amount of 
phosphorylated ERK rapidly from 2 min to 15 min after HMC-1 cells activation. 
Maximal phosphorylation was observed in 15 min and sustained to 30 min. 
Figure 4.7 shows that TLR7 ligand-mediated upregulation of surface 
expression of ICAM-1 and ICAM-3 were suppressed by the ERK pathway 
selective inhibitor PD98059 dose-dependently on HMC-1 cells. 
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Figure 4.6 Phosphorylation of ERK in TLR7-mediated HMC-1 cells activation. 
HMC-1 cells (3 x 10^ cells) were cultured with or without TLR7 ligand 
(20 jig/ml) for different indicated incubation times. Total cellular proteins were 
extracted from HMC-1 cells for the measurement of (A) phosphorylated ERK 
and (B) total ERK by Western blot analysis. Experiments were performed in 
three independent replicates with identical results and representative results are 
shown. 
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Figure 4.7 Effect of PD98059 on the TLR7—induced upregulation of adhesion 
molecules. HMC-1 cells (5 x 10^ cells) were pre-treated with PD98059 for 35 
min followed by incubation with or without TLR7 ligand (20 jiig/ml) in the 
presence of PD98059 for optimal incubation time (A) 24 h or (B) 48 h. Surface 
expressions of adhesion molecules of 10，000 viable cells of (A) ICAM-1 and (B) 
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ICAM-3 were analyzed by f low cytometry as mean fluorescence intensity (MFI). 
Results are expressed as the mean + SD from three independent experiments. 
DMSO (0.1 %) was used as the DMSO control. */? < 0.05 when compared with 
the R837 control. 
PD20: PD98059 (20^M) 
PD40: PD98059 (40^M) 
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4.2.5 Effect of TLR7 Ligand on HMC-1 Cells Cytokine Release 
Figure 4.8 shows the expression o f 79 common cytokines on HMC-1 cells. 
Treatment o f TLR7 ligand did not modulate cytokine secretion o f HMC-1 cells 
after 24 h incubation. The cytokine list wi th symbol and position information is 
given in the appendix. 
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Figure 4.8 Representative profile of the release of cytokines from TLR7 ligand 
treated HMC-1 cells. HMC-1 cells (2 x 10^ cells) were treated with or without 
TLR7 ligand (20 |Lig/ml) treatment for 48 h. Cell-free supernatant was then 
harvested and 79 different cytokines in the supernatant were semiquantitated 
using antibody-based RayBio human cytokine array V. Positive and negative 
controls were designated at ( la, lb, Ic, Id, 8j, 8k) and ( le. If , 8i), respectively. 
Triplicate experiments were performed with identical results. 
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4.3 Discussion 
TLR study on human mast cell is not as intensive as on other allergy 
associated leukocytes such as eosinophils, T-lymphocytes, neutrophils and 
macrophages, due to the difficulties in isolating and culturing primary mast cells. 
However, further understanding on the role o f TLR on mast cells may open up 
new possibilities concerning the role o f TLR in the pathogenesis of allergic 
diseases such as allergic asthma. 
The TLR expression profile of mast cell HMC-1 cells is different from 
eosinophils and neutrophils as it expressed T L R l , TLR2, TLR4, TLR5, TLR6, 
TLR7 and TLR9 only (Wong et al.’ 2007). This may imply a distinct role of mast 
cells in encountering viral and bacterial molecules. 
The main target of this study, TLR7, is located at endosomal membrane 
recognizing viral ssRNAupon viral infection (Diebold et al., 2004). In the mouse 
model, TLR7 is expressed in both skin derived and bone marrow derived mast 
cells (Matsushima et al., 2004). Recent study revealed that TLR7 ligand induced 
the production and secretion of proinflammatory cytokines and chemokines in 
mouse mast cells (Matsushima et al., 2004). In contrary, TLR7 ligand could not 
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induce the same effect on human mast cells. 
Regarding the effect on expression of adhesion molecules, TLR7 ligand 
could significantly upregulate the expression of adhesion molecule on human 
mast cells as in eosinophils (Nagase et al., 2003). ICAM-1 is an important cell 
surface adhesion molecule that binds to endothelial cells. In an allergic reaction, 
it is essential for f i rm adhesion o f mast cell on endothelial and epithelial cells, in 
order to facilitate migration to inflammatory sites (Shimada et al., 2003). In 
Crohn's disease and ulcerative colitis, characterized by mast cell hyperplasia and 
degranuation (van Assche et al., 2002), drugs or antibodies against ICAM-1 have 
been targeted for treatment by reducing mast cell accumulation (Nishibori et al, 
2003; Yacyshyn et al., 1999). In the mouse in vivo model, TLR7 ligand could 
induce transient systemic leukocyte depletion consequent to the leukocytes' 
rolling process on endothelial lining (Gunzer et al., 2005). Accordingly, 
TLR7-mediated upregulation of ICAM-1 expression on mast cells may modulate 
allergic response by enhancing cell trafficking. 
Apart from ICAM-1, it was found that ICAM-3 was also upregulated by 
TLR7 and resembled to allergic cytokine effects on eosinophils, thus may imply 
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linkage to allergic disease (Cheung et al., 2006). ICAM-3 is another key 
regulator of cellular adhesive properties as cross-linking enhances binding of 
leukocytes to matrix components o f inflamed tissues (Babina et al., 1999; 
Campanero et al., 1994; Cid et al., 1994). Moreover, ICAM-3 could facilitate 
mast cell homotypic aggregation through an LFA-1 independent binding (Babina 
et al., 1999). Mast cell accumulation therefore fiirther exacerbated the 
inflammatory process. 
In inflammatory allergic diseases such as asthma and rhinitis, disease 
exacerbation was reported to associate with viral infection (Murray et a/., 2004). 
Mast cells, which are the key effector leukocytes in allergic inflammation, may 
participate in the underlying pathogenesis. Both ICAM-1 and ICAM-3 not only 
resemble molecular glue, but a regulator in virus challenge. Asthma exacerbation 
is highly associated with the infection o f rhinoviruses (RV). RV are the most 
common causative agent of acute respiratory viruses and it is found in 85 % of 
the wheezing cases of children and 50 % cases of adult (Friedlander et al., 2005). 
At least 80 % of the approximately 100 identified serotypes of RV utilize human 
ICAM-1 as a cell-surface receptor (Greve et al., 1989). When mast cells were 
infected by RV, local inflammation was elicited by inducing the release of 
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inflammatory mediators (Hosoda et al., 2002). The reaction was further 
intensified by mast cell accumulation as ICAM-3 on mast cell surface could 
enhance homotypic aggregation (Kirchberger et al., 2006). Therefore，we 
postulated that TLR7 might provide a putative pathway for viral ssRNA to 
stimulate mast cells, followed by activation and exacerbation of local 
inflammation. 
Involvement of ERK pathway on regulating ICAM-1 surface expression was 
observed in this study. ERK has been reported to mediate TLR signaling in 
cytokine release, anti-apoptotic effect and Thl/Th2 polarization (Zhao et al., 
2007; Agrawal et al., 2006; Qian et al, 2006; Hacker et al., 2006). An additional 
function of ERK is to modulate adhesion molecule expression which has been 
reported in mast cell, eosinophils and neutrophils upon the stimulation by 
inflammatory cytokines (Cheung et al., 2006; Khreiss et a/., 2004; Tsang et al., 
2005). 
To summarize, this part of study is the first to describe TLR7-induced 
functional effects on human mast cells. Our results thereby provided some 
insights on how viral molecules activate mast cells. In the future, it may be 
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worthy to work on the expression and function of TLR7 on human mast cells 
from different tissue origins so as to obtain a fiill understanding on its role on 
human mast cells. 
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5.1 Conclusions 
In these experimental studies, we looked at the roles of mast cells in allergic 
inflammation in two different aspects. Firstly, we studied the effect of a mast cell 
specific protease, chymase, on human eosinophils. Eosinophil activation is 
essential in allergic diseases such as allergic asthma and AD (Leung, 2000; 
Rothenberg & Hogan, 2006). Secondly, we examined the response of mast cells 
upon the stimulation of TLR. TLR are important in innate immunity and 
currently found to be associated with allergic inflammation condition (Feleszko 
et al., 2006; Horner, 2006). Our findings in both parts could further elucidate the 
role of mast cells in mediating allergic inflammation. 
Mast cell chymase could increase the secretion of chemokines (CCL2, 
CXCLl and CXCL8) and enhance the chemokinesis, delayed apopotsis, thereby 
facilitating the accumulation of inflammatory cells. Furthermore, 
chymase-induced release of proinflammatory cytokine IL-6 could exaggerate the 
inflammation at the site of inflammation. As the majority of chymase producing 
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mast cells selectively located at skin (Prussin & Metcalfe, 2003), it is suggested 
that mast cell chymase may be a key player in skin allergic diseases such as AD. 
On the other hand, the profile of TLR expression profile in human mast cell 
was constructed by examining their protein expression. Among the TLR ligands, 
only TLR7 ligand could activate mast cell by upregulating the surface expression 
of adhesion molecules ICAM-1 and ICAM-3. In this study, we speculated that 
surface adhesion molecules not only increase mast cell density at the site of virus 
challenge, but also mediate viral infection, which is well-known in inducing 
asthma exacerbation (Come & Holgate, 1997). 
For the signaling mechanism, it is found that MAPK play an important role 
in regulating the mast cell mediating effects mentioned above. Both 
TLR7-induced effects on mast cells and chymase-induced secretion of IL-6, 
CXCL8 and CCL2 on eosinophils were mediated by the ERK pathway. The p38 
MAPK pathway was involved in the induction of all cytokines and upregulation 
of adhesion molecule CD 18 in chymase-activated eosinophils. Moreover, the 
N F - K B pathway, PI3K pathway and JAK-STAT pathway were also involved in 
various chymase effects. The data here suggests that the signaling pathways 
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underlying chymase action is complicated. 
5.2 Future Perspectives 
As chymase is related to AD inflammation, it may be worthy to extend the 
study on how chymase is related to this disease. Apart from Th2 predominance 
and leukocyte accumulation as discussed in this study, the possible role of 
chymase on other AD immunological consequences at the lesion site such as 
lichenification, epidermal hyperplasia and dermal fibrosis could be explored 
further. These can be achieved by measuring the release of other eosinophil 
mediators such as eosinophil-derived neurotoxin, major basic protein and 
eosinophil peroxidase. All of them are involved in the direct tissue damages at 
the site of lesion. Besides, chymase effect on other leukocytes such as different T 
lymphocyte subsets, neutrophils and fibroblasts will also help us understand 
more of the role of mast cell in AD progression. At the biochemical basis of 
chymase action, we shall also look for the receptor of chymase on human so as 
to develop anti-chymase therapy by specifically inhibits its receptor. 
Besides releasing mediators, mast cells may also communicate with other 
cells by direct cell-cell interaction. Previous study by our group showed that 
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eosinophils could activate epithelial cells (BEAS-2B) to release cytokines, 
chemokines and upregulate the expression of adhesion molecules, thereby 
promote leukocyte recruitment at the site of inflammation (Wong et al., 2006). 
The coculture of mast cells and epithelial cells could mimic the in vivo condition, 
so as to understand the pathological consequences of mast cell accumulation in 
allergic asthma. 
TLR has shown increasing important on their role in mediating allergic 
reaction. However, not much information about the TLR-mediated effects on 
mast cells is available. In the future, it may be valuable to work on the 
expression and function of TLR7 on human mast cells from different tissue 
origins so as to obtain a better understanding of its role on human mast cells. As 
we have suggested that TLR7-mediated ICAM-1 upregulation could enhance RV 
infection, the hypothesis could be investigated by studying the infectivity of RV 
on mast cells with or without TLR7 activation. 
Moving forward to our next step from understanding the immunology of 
mast cells in allergic disease to therapeutic purpose, it would also be beneficial to 
study chymase inhibitors or signaling molecule inhibitors so as to reduce 
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inflammation and relieve the symptoms of allergic diseases. In fact, some of the 
applications of inhibitors on treating allergic disease are in progress in mouse 
model (Tomimori et al., 2002; Watanabe et al., 2002). Further study in the 
mechanism of how these inhibitors on chymase action would provide 
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Cytokine map of RayBio human cytokine array V 
Location Abbreviation Name of cytokine 
al Pos Positive control 
a2 1-309 CC Chemokine 1-309 
a3 IL-12p40p7Q IL-12 
a4 MIP-15 Macrophage inflammatory protein-15 
a5 Oncostain M Oncostain M 
a6 FGF-4 Fibroblast growth factor-4 
a7 IGFBP-3 Insulin-like growth factor binding protein-3 
a8 NT-4 Neurotrophin-4 
bl Pos Positive control 
b2 IL-1 a IL-1 a 
b3 IL-13 IL-13 
Regulated upon activation, normal T-cell 
b4 RANTES , , , 
expressed, and secreted 
b5 Thromopoietin Thromopoietin 
b6 FDF-6 Fiber differentiation factor-6 
bl IGFBP-4 Insulin-like growth factor binding protein-4 
b8 Osteoprotegerin Osteoprotegerin 
cl Pos Positive control 
c2 IL- lp IL- lp 
c3 IL-15 IL-15 
c4 SCF Stem cell factor 
c5 VEGF Vascular endothelial growth factor 
c6 FGF-7 Fibroblast growth factor-7 
c7 IL-16 IL-16 
c8 PARC Pulmonary and activation-regulated chemokine 
dl Pos Positive control 
d2 IL-2 ^ 
d3 IFN-丫 IFN-丫 
d4 SDF-1 Stromal cell-derived factor-1 
d5 PDGF-BB Platelet-derived growth factor-BB 
d6 FGF-9 Fibroblast growth factor-9 
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d7 IP-10 Interferon inducible protein 10 
d8 PIGF Placenta growth factor 
el Neg Negative control 
e2 IL-3 IL-3 
e3 MCP-1 Monocyte chemotactic protein-1 
e4 TARC Thymus and activation-regulated chemokine 
e5 Leptin Leptin 
e6 FIT-3 Ligand FIT-3 Ligand 
e7 LIF Leukemia inhibitory factor 
e8 TGF-p2 Transforming growth factor- (32 
f l Neg Negative control 
f2 IL-4 ^ 
f3 MCP-2 Monocyte chemotactic protein-2 
f4 TGF-pl Transforming growth factor- (31 
f5 BDNF Brain-derived neurotrophic factor 
f6 Fractalkine Fractalkine 
Lymphotoxins, inducible expression, competes 
f7 LIGHT with HSV glycoprotein D for HVEM, a receptor 
expressed on T-lymphocytes 
f8 TGF-P3 Transforming growth factor- P3 
gl ENA-78 Epithelial neutrophil activating peptide 
g2 ^ ^ 
g3 MCP-3 Monocyte chemotactic protein-3 
g4 TNF-a Tumor necrosis factor-a 
g5 BLC B lymphocyte chemokine 
g6 GCP-2 Granulocyte chemotactic peptide-2 
g7 MCP-4 Monocyte chemotactic protein-4 
g8 TIMP-1 Tissue inhibitor of metalloproteinase-1 
hi GCSF Granulocyte-colony stimulating factor 
h2 ^ ^ 
h3 MCSF Macrophage colony stimulating factor 
h4 TNF-P Tumor necrosis factor-p 
h5 Ck betaS-1 CC chemokine CK betaS-1 
h6 GDNF Glial cell line-derived neurotrophic factor 
hi MIF Macrophage migration inhibitory factor 
h8 TIMP-2 Tissue inhibitor of metalloproteinase-2 




12 IL-7 IL-7 
13 MDC Macrophage Derived Chemokine 
14 EGF Epidermal growth factor 
is Eotaxin Eotaxin 
16 HGF Hepatocyte Growth Factor 
17 MIP-3a Macrophage inflammatory protein-3a 
18 Neg Negative control 
j 1 GRO Growth regulated oncogene 
j2 IL-8 IL-8 
j3 MIG mMonokine induced by interferon-y 
j4 IGF-1 Insulin-like growth factor-1 
j5 Eotaxin-2 Eotaxin-2 
j6 IGFBP-1 Insulin-like growth factor binding protein-1 
]1 NAP-2 Neural antiproliferative protein-2 
j8 Pos Positive control 
kl GRO-a Growth regulated oncogene-a 
k2 IL-10 IL-10 
k3 MIP-lp Macrophage inflammatory protein-1(3 
k4 Angiogenin Angiogenin 
k5 Eotaxin-3 Eotaxin-3 
k6 IGFBP-2 Insulin-like growth factor binding protein-2 
k7 NT-3 Neurotrophin-3 
k8 Pos Positive control 
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